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CHAPTER 1
INTRODUCTION
1.1 Small cell lung cancer
Human small-cell lung carcinoma (SCLC), accounting for approximately  15-20% 
of all lung cancers, is an aggressive tumor with a high propensity for early 
regional and distant metastases. Chemotherapy is the primary treatment option 
for patients with SCLC, leading to a 5 year survival of approximately 20% in 
limited disease (LD) and less than 5% in extensive disease (ED). Although the 
initial response rate to chemotherapy is very high (up to 96% for LD and up to 
65% for ED), SCLC relapses after approximately 4 months in ED and 12 
months in LD (Figure 1). [Govindan R. et al 2006].
Fig.1 Govidan R.et al 2006
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SCLC is strongly associated with cigarette smoking (Figure 2). [Chikako K. et al 
2010]
Fig.2 NIH analysis
Improving the survival rate of patient with SCLC requires a better understanding 
of tumor biology and the subsequent development of novel therapeutic 
strategies. Molecular analysis of lung cancer has provided a large amount of 
information on the molecular abnormalities that are more specific to SCLC. 
These alterations have been used as targets for new biologic therapies, such as 
those that focus on cell signalling and other biologic pathways involved in 
tumorigenesis.
1.1.1 Etiopathogenesis and inheritance
Small cell lung cancer, also known as Microcitoma, arises from cells defined as 
pulmonary neuroendocrine cells (PNECs). These cells, although widely 
distributed in organs and tissues without any neuroendocrine functions, are able 
to secrete hormones. They show unique morphologic features, secrete several 
biologic compounds and express neuroendocrine markers. 
During lung development, PNECs are the first cells to form and differentiate 
within the primitive epithelium, reaching a peak during the neonatal period, 
thereafter they persist throughout life as a viable population. [Gosney JR et al 
1993].
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Although the origin of PNECs has not been fully determined, the endodermal 
origin of this cells is general accepted, since PNECs occur in immature fetal 
epithelium in vitro and neuroendocrine carcinomas such as SCLC seem to be 
derived from normal epithelium. [Ito T. et al 1997]
PNECs are distributed throughout the airway epithelium from the lobar 
bronchus to the alveolar duct as single cell but sometimes they form clusters 
called neuroepithelial bodies (NEBs). NEBs are localized only  in the 
intrapulmonary airway. Even though their precise role is unclear the PNECs/
NEBs complex represents the lung staminal niche that plays a central role in 
regeneration and lung carcinogenesis. [Cutz E. et al 2007]
In the healthy adult, PNEC are sparsely distributed, with approximately 1 PNEC 
per 2500 epithelial cells. The secretory granule-containing cells are typically tall 
and pyramidal in shape, extending from the basal lamina of the epithelium and 
possess apical microvilli projecting into the airway lumen. These microvilli 
function as the sensory part of the cell and upon stimulation, respond by 
degranulation and exocytosis of amines and neuropeptides, which exert a local 
paracrine and neurocrine effect on neighboring cells and activate both extrinsic 
and intrinsic neurons (Figure 3). [Adriansen et al. 2006; Gustafsson et al. 2008]
Fig. 3 Mechanism of hypoxia-induced degranulation of NEBs (green). The released dense core 
vesicles (red) contain signal substances including serotonin, CGRP, bombesin, calcitonin, 
enkephalin, somatostatin, and cholecystokinin, which activate vagal and DRG  afferent neurons 
as well as adjacent epithelial, vascular, or smooth muscle cells. DRGs in turn activate intrinsic 
efferent neurons facilitating feedback signaling to the NEBs. A single pulmonary neuroendocrine 
cell (PNEC) (yellow) with basal extension provides paracrine influence on adjacent mucosal 
cells.
Although most PNECs exist as solitary cells, some are aggregated in innervated 
PNEC clusters referred to as neuroepithelial bodies (NEBs). Both solitary 
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PNECs and NEB exhibit similar phenotypes in terms of storage of adenosine 
triphosphate, serotonin (5- HT), and several other amines and neuropeptides in 
dense-core vesicles. Serotonin and other peptides (eg. bombesin, calcitonin) 
with growth factor-like properties are thought to play  an important role in normal 
lung development. [Pan J. et al. 2006]
SCLC arise from bronchi, the WHO classification defines SCLCs as 
neuroendocrine tumors with >10 mitoses/2 mm2 and small cell cytologic 
features. The cellularity is typically very high, with hyperchromatic nuclei, absent 
or very small nucleoli with scant cytoplasm, and a round or fusiform shape and 
a very high mitotic rate. SCLC may occur in combination with non small-cell 
lung cancers as well as with other LCNEC. In combination with the histologic 
appearance, the cell proliferation marker Ki-67 (as per the WHO classification of 
mitotic counts) seems to be the most useful marker to distinguish between the 
different subgroups of BP-NETs. A variety  of peptide and amine markers 
including chromogranin A (CgA), neuron-specific enolase (NSE), serotonin, 
synaptophysin, and adrenocorticotrophic hormone (ACTH) have some utility in 
establishing the differential diagnosis.
Metastases are usually seen within intrathoracic lymph nodes, but distant 
metastases to the liver, skeleton, central nervous system (CNS), skin, and 
mammary glands occur.
1.1.2 Diagnosis and Staging
SCLCs do not cause any  symptoms until they have spread too far to be cured, 
but some people with early lung cancer do have symptoms. The most common 
symptoms of SCLC are: cough that does not go away or gets worse; chest pain 
that is often worse with deep  breathing, coughing, or laughing; hoarseness; 
coughing up blood or rust-colored sputum (spit or phlegm); shortness of breath; 
feeling tired or weak; infections such as bronchitis and pneumonia that don’t go 
away or keep coming back. 
When lung cancer spreads to distant organs, it may cause: weight loss and loss 
of appetite; bone pain (like pain in the back or hips); neurologic changes (such 
as headache, weakness or numbness of an arm or leg, dizziness, balance 
problems, or seizures).
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SCLC has been staged as:
Limited disease (LD): restricted to 1 hemithorax with regional lymph node 
metastases, including hilar, ipsilateral, and contralateral mediastinal and 
ipsilateral and contralateral supraclavicular nodes. Median survival is 12-20 
months with a 5-year survival of less than 5%. [Micke P. et al. 2002]
Extensive disease (ED): presence of obvious metastatic disease. Median 
survival is 7-12 months, with a 5-year survival less than 2%.
In a new proposal from the International Association for the Study of Lung 
Cancer (IASLC), however, TNM staging (Tumour, Node, Metastases) is also 
suggested for SCLC, and it has been recommended that it be evaluated in 
clinical trials.
The most common metastatic sites for SCLC are bone (19%-38%), liver 
(17%-34%), the adrenal glands (10%-17%), and the brain (up to 14%). [Simon 
C. et al. 2001]
1.1.3 Genetics of SCLC
In the past two decades, significant progress has been made in understanding 
the molecular and cellular pathogenesis of lung cancer. Abnormalities of proto-
oncogenes, genetic and epigenetic changes of tumour suppressor genes, the 
role of angiogenesis, molecular abnormalities in pre-invasive respiratory lesions 
have recently come into focus.
The major histopatological differences between SCLC  and NSCLC are due to 
distinct genetic alterations [Zochbauer-Muller S. 2002]. For example, RAS 
oncogene mutations have been detected in 15-20% of all NSCLC but never 
found in SCLC, whereas abnormal MYC expression, MYCN and MYCL1 in 
particular, is frequently observed in SCLC  but is less common in NSCLC. 
[Meuwissen et al. 2005]
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Primary chromosomal alterations
Several sites of frequent allelic loss have been identified in lung cancer [Girard 
L.et al. 2000]. The location of these sites was based on the determination of the 
minimal regions of loss that are defined by the occurrence of breakpoints 
(transitions between markers showing LOH and those retaining heterozygosity) 
surrounding regions of LOHs. These sites are likely  to represent the major TSG 
regions that are affected in lung cancer and are therefore good indicators of 
critical regions of loss that warrant further investigation. It was shown previously 
that chromosome arms 3p have the most frequent allelic loss in SCLC (90%), in 
several sites, including FHIT (fragile histidine triad) locus, RASSF1 (ras effector 
homologue) locus, RARB (retinoic acid receptor beta) locus, FUS1 and PTEN 
loci.
Oncogene activation
Proto-oncogenes MYC, MYCL, MYCN are usually  activated in SCLC and they 
represent a marker for a poor prognosis. [Johnson B.E. et al. 1996]
BCL-2 is an anti apoptotic protein expressed in 75-95% of SCLC cases [Jiang 
S.X. et al. 1995]. BCL-2 works against a pro-apoptotic protein BAX, a p53 
target. High levels of BCL2 and low levels of BAX have been frequently found in 
SCLC p53-/- [Brambilla E. et al. 1996]. Moreover SCLC with high expression of 
BCL2 are associated with a high sensitivity to chemotherapy.
Oncosuppressor deactivation
p53 is a nuclear phosphoprotein, that function as a transcription factor. The 
human gene is located on chromosome 17 and mouse gene on chromosome 
11, it encodes a tetrameric polypeptide of 393 amino acids. p53 binds a 
consensus sequences on the DNA and it activates or represses the 
transcription of several genes. Depending on what type of genes p53 activates, 
that it can stimulate apoptosis or inhibit cell cycle progression or promote DNA 
repair or induce differentiation. Normally p53 intracellular levels are low 
because the protein is rapidly degraded by ubiquitin-dependent proteolysis 
induced by Mdm2 factor. Following stress signals p53 can be activated with a 
consequent increase of intracellular levels. This increase is mainly due to an 
increase of the stability  of the protein, but we cannot exclude the presence of a 
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transcriptional or translational control. The stress signals that activate p53 are 
represented by  DNA damage, chromosomal aberrations, oncogenes activities, 
hypoxia, shortening of telomere, lack of growth factors. [Khanna K.K. et al. 
2001]
Mutations in p53 or alterations in the p53 pathway are frequent in human 
tumours. p53 is involved in both hereditary and sporadic tumours. Mutations in 
p53 are found in 50% of sporadic human cancers. These mutations affect 
mainly exons 5, 6, 7, 8 8. p53 loss of function is frequently found in SCLC.
p16INK4A-cyclin D1-CDK4-RB pathway plays a central role in the cell cycle G1/S 
transition and alterations of one of his components is frequently found in lung 
cancer and in the 90% of SCLC RB protein is inactive.[Reissmann P.T. et al. 
1993]
Moreover p14ARF is mutated in 75% of all SCLCs.
Angiogenesis and metastasis
Recent evidence suggests that the genetic regulation of angiogenesis is also of 
crucial importance and that oncogenes and tumour suppressor genes can 
regulate it [Onn A. et al. 2003]. Vascular endothelial growth factor (VEGF) is a 
multifunctional cytokine that increases microvascular permeability and directly 
stimulates endothelial cell growth and angiogenesis. Expression of VEGF is 
correlated with loss of p53.[Niklinska W. et al. 2001]
Also the MMP family and their inhibitors plays a central role in metastasis and 
tumor associated angiogenesis.[Chambers A.F. et al. 1997; Nelson A.R. et al. 
2000]
The complex E-caderin-catenin plays a central role in the architectural structure 
tissue maintenance [Bremnes R.M. et al. 2002]. Loss of E-caderin expression at 
the metastasis level is associated with a poor outcome.[Hirata T. et al. 2001; 
Kalogeraki A. et al. 2003]
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1.2 MYCN Gene
1.2.1 MYC gene family
MYC genes are frequently  involved in human cancers. The family  of proto-
oncogenes MYC is composed of a group of transcription factors belonging to 
the class basic-helix-loop-helix-zipper (bHLHZ) [Eilers M. et al. 1991]. The Myc 
proteins family is involved in the regulation of proliferation and cell cycle, in the 
processes that lead to differentiation and to apoptosis, in genomic instability and 
neoplastic transformation [Grandori C. et al. 2000; Nesbit C.E. et al. 1999]. Most 
studies on MYC genes are focused on three members (c-MYC, MYCN and L-
MYC), which, when activated, appear to be important in the development of 
various human cancers. c-MYC was the first of the three to be discovered 
through its homology with v-MYC, the transforming gene of the MC29 virus of 
avian myelocyticomatosis [Vennstrom B. et al. 1982]. MYCN and L- MYC were 
subsequently  identified through their homology with v-MYC amplicons in the 
cells, respectively, of neuroblastoma and small cell lung cancer [Schwab M. et 
al. 1983; Nau M.M. et al. 1985]. The MYCN oncogene, in particular, was 
identified in 1983, in neuroblastoma cell lines with DMs (double minute 
chromatin bodies) and / or HSRs (homogeneously staining regions) [Schwab  M. 
et al. 1983; Kohl N.E. et al. 1983].In situ hybridization allowed us to locate 
human MYCN on the short arm of human MYCN distal chromosome 2, region 
2p  23-24. Only the second and third exons of the gene are translated and they 
lead to the formation of the protein. Other genes, at least three, belong to this 
family: S-MYC, B-MYC and P-MYC. The MYC genes can be activated through 
different mechanisms such as gene amplification [Dalla-Favera R. et al. 1982], 
chromosomal translocation [Magrath I. et al. 1990], proviral insertion [Payne 
G.S. et al. 1982], retroviral transduction [Neil J.C. et al. 1987] and other 
processes not yet known. The members of this family play a key role in 
activating and controlling gene expression: infact, they  have the same structural 
motifs of many transcriptional factors, like oncoproteins v-Fos and v-Jun, 
leucine-zipper motifs are set in the C-terminus of the protein where, due to their 
α-helices, they are able to wrap the DNA [Landschulz W.H. et al. 1988]. Before 
the C-terminus, there is a helix-loop-helix domain, already identified in several 
transcription factors, such as proteins E12 and E47 [Murre C. et al. 1989]. The 
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proteins also contain a stretch of basic amino acids upstream of helix-loop-helix 
motif, called "basic region”, previously identified in the myogenic transcription 
factor MyoD, which is the region involved in sequence-specific DNA binding 
[Davis R.L. et al. 1990]. Considering all these structures MYC gene family 
contains a motif of bZIP- bHLH able to interact with DNA in which the bZIP and 
bHLH domains lie in adjacent positions separated by only  a basic domain "b". 
Unlike normal bHLH domains, it allows fusion of that structure to hang the DNA 
through the basic regions of bHLH motif, while any dimerization (Myc-Max) of 
protein monomers are guaranteed by the bZIP motif (Figure 4).
Fig. 4 Structure of a bZIP-bHLH motif: Myc-Max heterodimer and the binding with DNA.
1.2.2 From MYCN gene to N-Myc protein
The post-transcriptional regulation of MYCN is influenced by a ribosomal 
internalization signal located at mRNA 5'-UTR, which amplifies the translation 
initiation and determines the redistribution in the cytoplasm [Jopling C.L. et al. 
2001]. The N-Myc degradation in neuroblastoma is ATP dependent and it is 
mediated by  the 26S proteasome in the nucleus; degradation can however be 
done by the employee via calpain [Bonvini P. et al. 1998].
MYCN is as a classic dominant oncogene. The forced expression of MYCN can 
transform normal cells, usually in cooperation with RAS oncogene [Yancopoulos 
G.D. et al. 1985; Schwab  M. et al. 1985; Small M.B. et al 1987]. The over-
expression of MYCN can release the embryonic fibroblasts from senescence 
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[Schwab M. et al. 1988], the addition of an RNA antisense MYCN in 
neuroblastoma cell lines that over-express MYCN can reduce the proliferation 
or induce differentiation and / or apoptosis [Negroni A. et al. 1991; Schmidt M.L. 
et al. 1994]. Moreover, the over-expression of human MYCN in the 
neuroectoderm of the transgenic TH-MYCN mouse produces, in a dose-
dependent way, neuroblastoma resembling tumors [Weiss W.A. et al. 1997].
N-Myc protein is a nuclear phosphoprotein with a short half-life (30-50 min) and 
it shows regions of high homology (overall 38% amino acid identity) with c-Myc. 
N-Myc, like all the Myc family proteins, has three specific amino acid sequences 
[Pession A. et al. 2005]:
• a globular domain of transactivation in N-terminus, containing the Myc Boxes I 
(MBI) and II (MBII);
• an unstructured intermediate region;
• a C-terminus domain containing a basic region (BR), which is involved in the 
recognition and specific binding to DNA.
Myc forms complexes with DNA only at very high concentrations, indicating that 
these interactions may not be physiologically significant. It is possible that Myc 
required interaction with a second protein to play its role as a transcription 
factor. This was subsequently identified in a small protein called Max 
[Blackwood E.M. et al. 1991].
Max is a ubiquitous nuclear protein with a long half-life, and like Myc, contains 
the helix-loop-helix and leucine-zipper basic motif. Max binds to itself and to 
other transcription factors through its leucine zipper to form homo- and hetero-
dimers respectively. Max itself lacks a transactivation domain so that Max 
homodimers have a repressive function. In contrast, Myc contains a 
transactivation domain but cannot homodimerize. However Myc can 
heterodimerize with Max to form heterodimers that can both bind DNA and 
transactivate. The transcriptionally active Max/Myc dimer promotes cell 
proliferation as well as apoptosis. [Amati B. et al. 1994]
This complex binds specifically  to a palindromic nucleotide sequence CACGTG 
on DNA, called E-box [Solomon D.L. et al. 1993]; another binding site between 
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on DNA is an asymmetric sequence CATGTG. Other transcription factors such 
as USF, TFE3 and TFEB binds to these sequences. This leads to a great series 
of transcriptional activation of genes that promote cell growth. [Grandori C. et al. 
1997]
Despite the structural and functional homology, the expression of c-Myc and N-
Myc is very different: c-Myc is ubiquitous expressed in proliferating cells, while 
N-myc has a pattern of expression quite restricted [Strieder V. et al. 2002]. 
Development studies on mouse show that N-myc is mainly expressed during 
the early stages of differentiation: at birth it’s still expressed in brain, kidney, 
intestines, heart and lungs, but it is subsequently down-regulated and in the 
adult mouse its expression occurs mainly in the early  development of B 
lymphocytes [Wakamatsu et al. 1997; Strieder V. et al. 2002].
The transcript of N-myc is rather complex: it begins in different sites that can be 
grouped under the control of two promoters; the multiplicity of start sites to start 
combines with alternative splicing to generate two forms of mRNA. The mRNAs 
have different 5' leader sequences but identical structure. Both forms of mRNA 
are unstable with a half-life of 15 min. They encode the two N-myc proteins of 
65 and 67 kD. [Stanton L.W. et al. 1987]
1.2.3 Role of MYCN in small cell lung cancer
MYCN amplification was found first in human neuroblastoma in 1983 by 
Schwab and colleagues. Following studies have confirmed that the presence of 
more than 10 copies of MYCN gene per haploid genome is an unfavorable 
prognostic marker, independent from other parameters. 25-30% of primary 
untreated NB shows the amplification of MYCN, which is associated with 
advanced disease, rapid progression and poor prognosis [Sansone R. et al. 
1991]. The reason of this association is still uncertain. There is also a direct 
correlation between the levels of N-Myc protein and the aggressiveness of this 
tumour. The MYCN amplification was identified as a single genetic factor which 
adds a prognostic significant information to clinical variables such as age and 
stage, infact, currently the status of MYCN is the only genetic variable of cancer 
used as a criterion for stratification of treatment in clinical trials of NB [Berthold 
F. et al. 1997]. In 1997 Weiss W.A. and his group showed that MYCN 
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contributes to the genesis of neuroblastoma with the generation of a transgenic 
mice that over-express MYCN in neuro-ectodermal cells and for this they 
develop neuroblastoma.
The amplification of MYCN is associated with the development of several 
pediatric tumors, as well as NB: glioblastoma (< 5%), medulloblastoma (5-15%); 
and other adult solid tumors: melanoma of neuroectoderm tumor, astrocytoma, 
retinoblastoma (10-20%) and cell lung cancer (10%). In general, overexpression 
of the MYC family oncognes is a frequent molecular alteration in SCLC, 
occurring in 18-31% of SCLCs, and more common in chemo-refractory disease. 
[Wistuba et  al. 2001] 
Kim and colleagues in 2006 identified novel alterations in SCLC performing 
comparative genomic hybridization on a set of 24 SCLC cell lines, using cDNA 
microarrays representing 22000 human genes (providing an average mapping 
resolution of <70kb). They identified DNA amplifications corresponding to 
oncogenes known to be amplified in SCLC, including MYC  (8q24), MYCN 
(2p24) and MYCL1 (1p34). Their findings support a role of altered apoptotic 
balance in the pathogenesis of SCLC, and suggest that MYC family genes 
might affect oncogenesis through distinct sets of targets, in particular implicating 
the importance of transcriptional repression. [Kim YH. et al. 2006]
1.3 Therapeutic options and chemotherapy
SCLC is distinguished from the other forms of lung cancer by its aggressive 
clinical course, with widespread metastases at diagnosis, the frequent 
occurrence of para-neoplastic syndromes [Lally BE. et al 2007], and its 
sensitivity to both chemotherapy and radiotherapy; Small cell lung cancer 
(SCLC) now represents only 13% of all newly diagnosed lung cancers, annual 
incidence of SCLC has been decreasing over the past 30 years. [Puglisi M. et 
al. 2010]
As already mentioned SCLC can be staged in limited disease and extensive 
disease.
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1.3.1 Treatment of limited disease
The survival of patients with LD-SCLC has improved over the past 20 years, 
with a 5-year survival rate of 13.9% compared with 6% before 2000 [Puglisi M. 
et al. 2010]. The positive outcome in LD seems to be multifactorial, with better 
staging, platinum-based chemotherapy and the use of prophylactic cranial 
irradiation (PCI) all exerting an effect. The addition of TRT to chemotherapy, 
both sequentially  and, more recently, concomitantly, significantly reduces the 
risk of intrathoracic failures, resulting in improvements in long-term survival in 
this population.
The function of surgery has never been fully  developed because of the apparent 
failure of this treatment modality in two randomized trials reported in 1976 and 
1994. Both trials did not show any survival advantage for surgery alone or in 
combination with TRT, compared with radiotherapy alone [Fox W. et al. 1973; 
Lad T et al. 1994]. A recent review of these data suggests that the ‘intention to 
treat’ results may have misrepresented the effect of surgery, as not all patients 
randomized to surgery and included in the analyses actually underwent a 
complete resection. Infact, only  48% and 77% of patients, respectively, did so, 
meaning that the impact of surgery may have been underestimated [Lim E. et 
al. 2008].
Other published prospective series also suggest that surgery, after induction 
chemotherapy, can achieve high local control rates in early stage SCLC (stage I 
– III) with favorable long-term survival results. To validate this hypothesis, a 
number of randomized trials have recently  been designed to compare surgery, 
in combination with chemotherapy or chemo-radiotherapy, with the current 
standard of treatment with chemo-radiotherapy using modern staging methods.
Combined modality  therapy with chemotherapy and thoracic irradiation is the 
current accepted standard for patients with LD- SCLC (NCCN, 2008).There are 
a number of unresolved issues in the delivery of chemotherapy and radical 
radiotherapy in LD-SCLC including timing of TRT, early vs late, concomitant or 
sequential, total dose and fractionation schedule. Many trials have addressed 
the timing issues, but they have differed in trial design as well as the 
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chemotherapy regimen used as reviewed recently by Socinski and Stinchcombe 
(2007).
Etoposide (EP) remains the only chemotherapy that can be delivered at full 
dose in combination with radiotherapy in LD-SCLC.
1.3.2 Treatment of extensive disease
Chemotherapy is the main treatment for ED-SCLC. Treatments in the past 
including oral Etoposide, standard and high-dose regimens have been 
extensively reviewed by the authors in an earlier publication [Popat and O’Brien, 
2005]. Combination therapy with EP is considered the standard first-line 
regimen, but a randomized Phase III trial failed to prove a definitive survival 
benefit for EP compared with the cyclophosphamide, doxorubicin and vincristine 
regimen (CAV).
A study conducted by the Japan Clinical Oncology Group showed a significant 
survival benefit for irinotecan and cisplatin combination vs EP, but a second 
study in US patients of the same agents failed to show any significant 
difference.[Okamoto H. et al.2007]
The GC  chemotherapy (gemcitabine plus carboplatin) achieved survival rate, 
response rate and time to progression equivalent to EP. The two regimens had 
a different toxicity profile. The GC  regimen is useful, particularly in patients with 
mixed small cell and non-small cell tumours, and for those for whom alopecia is 
a real problem.
To summarize these results, all the recent randomized trials using later 
generation cytotoxics have not had a significant impact on standard care for 
SCLC, failing to identify a new platinum-based combination over the established 
platinum etoposide.
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Table 1 Phase II/III studies of combination chemotherapy in patients with ED-SCLC
1.3.3 Treatment options for relapsed SCLC
Despite high initial response rates to chemotherapy, SCLC usually recurs within 
1 year after treatment.
On the basis of retrospective data, distinction has been made between (1) 
sensitive patients, that is those with a response to first-line therapy and a 
treatment-free interval of at least 90 days, (2) resistant patients, that is relapse 
within 90 days and (3) refractory patients, that is no response to first-line 
treatment. [Fischer B., Arcaro A. 2008]
Single-agent Topotecan is currently the only approved drug for the treatment of 
patients with SCLC who have failed or relapsed after first-line chemotherapy. 
Topotecan is available in both intravenous and oral formulations and 
randomized studies have suggested that both have similar clinical activity in 
SCLC. A randomized Phase III trial has shown significant benefit with oral 
topotecan plus best supportive care vs best supportive care only in relapsed 
patients unsuitable for intravenous regimens [Gralla RJ et al. 2004]. There are 
several ongoing trials for this stage.
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1.3.4 Target therapies
During the last decades, target therapies have been developed by several 
pharmaceutical companies, but only few clinical trials have obtained 
encouraging results.
Ongoing trials are focusing on molecules against the proliferative, antiapoptotic 
and angiogenic pathways.
Ras/Raf inhibitors. The ras family genes have been identified as potential 
targets for therapeutic intervention because of somatic mutations in different 
human cancers. They are mutated in non-small cell lung cancer (NSCLC) 
approximately  20% of the time. The enzyme farnesyl transferase is involved in 
post-translational modification of the ras proteins by covalently linking a farnesyl 
group to the ras protein. This permits the ras protein to be translocated to the 
surface membrane, allowing the protein to be involved in signalling for 
increased proliferation and inhibition of apoptosis. The class of farnesyl 
transferase inhibitors is designed to block farnesylation and prevent the mature 
ras signalling and thus inhibit cell proliferation and facilitate apoptosis. Multiple 
agents that inhibit farnesylation have been developed, and two farnesyl 
transferase inhibitors have been tested in patients with lung cancer in three 
Phase II trials. R115777 has been studied in patients with NSCLC and in 
patients with relapsed small cell lung cancer (SCLC) after chemotherapy. There 
has been a single trial of L-778,123 in patients with untreated NSCLC [Seep-
Lorenzino et al. 1995]. There were no objective responses among the 22 
patients with relapsed SCLC treated with R115777. [Jonson BE. et al. 2004]
C-kit pathway inhibitors. More than 70% of SCLC cell lines and tumor 
specimens co-express Kit and its ligand SCF, leading to the hypothesis that this 
co-expression constitutes an autocrine growth loop. A study by Krystal and coll. 
showed that Imatinib, a tyrosine kinase inhibitor c-KIT and PDGFR specific, 
arrests SCLC cell line growth [Kristal GW. et al 2000]. This study led to several 
clinical trials with no significant results.[Shneider BJ. et al 2006; Spigel DR. et 
al. 2007]
IGF1R/PIK3/AKT1/FRAP1. Evidence suggests that the PI3K/Akt pathway 
(mTOR) may be important in proliferative and anti-apoptotic signalling in SCLC. 
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This may be responsible for the chemo-resistance to Imatinib  [Tsurutani J. et al. 
2005]. A new IGF1R inhibitor, NVP-ADW742, enhances SCLC cell lines 
chemotherapy sensitivity [Krystal GW. et al. 2005] and monoclonal antibodies 
are currently  been studying in clinical trials to be used in combination with 
chemotherapy and other target therapies.
Anti-angiogenic treatments Currently, only Bevacizumab  has demostrated an 
overall survival in extensive SCLC, but clinical trials are still ongoing.
Immunotherapy: The BEC2/BCG (Bacillus Calmette-Guérin) vaccine was 
studied extensively in SCLC over the past decade and ultimately failed to 
achieve a significant benefit in OS. Ipilimumab  is currently the subject of a 
phase III clinical trial to determine whether blockade of CTLA-4 in patients with 
extensive-stage SCLC enhances antitumor T-cell.
1.4 Peptide Nucleic Acid 
1.4.1 Structure and properties
The PNAs are synthetic analogs of nucleic acids, in which the normal 
phosphodiester backbone is replaced by a pseudo-peptide chain composed of 
monomers of N-(2-aminoethyl) glycine.[Nielsen P.E. et al. 1991]
The PNA binds sequence-specific DNA and RNA according to the rules of 
Watson-Crick pairing.[Egholm, M. et al. 1994]
The PNAs are achiral and non-ionic molecules; PNA oligomers also show 
greater specificity in binding to complementary DNAs, with a PNA/DNA base 
mismatch being more destabilizing than a similar mismatch in a DNA/DNA 
duplex. PNAs are not easily  recognized by either nucleases or proteases, so 
they are not degraded in cells and are extremely stable in biological fluids.
[Demidov V.V. 1994]
The compounds are neutral and therefore have a low solubility in water 
compared to DNA. The neutral PNA molecules have a tendency to form 
aggregates in the nucleotide sequence-dependent manner. The solubility  of 
PNA is also linked to the length of the oligomer and the purine relationship: 
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pyrimidine [Hyrup  B. et al. 1996]. Some modifications, including the 
incorporation of positively charged lysine residues, can improve solubility. To 
increase the solubility  in water, negative charges can also be introduced, 
especially in the PNA-DNA chimeras.
The concentration of a PNA oligomer is determined by measuring the 
absorbance at 260 nm at 80°C [Kuhn H. et al. 1998]. At this temperature, the 
nitrogen bases are considered completely detached and the disruption of π 
system by the peptide skeleton takes less important.
PNAs bind preferentially to the complementary  sequences; more weakly  to 
those containing a mismatch. [Nielsen P.E. et al. 1993]
1.4.2 PNA anti-gene
The PNA interferes with gene expression through two mechanisms [Ray A. et 
al. 2000]:
• anti-gene strategy: through inhibition of transcription by binding to DNA;
• anti-sense strategy: through inhibition of translation by binding to mRNA.  
The anti-gene strategy has the advantage, compared with antisense, to block 
the gene of interest even before it is transcribed: this allows to be used at lower 
concentrations and shows a stronger inhibitory and prolonged over time 
compared to antisense. [Pession A. et al. 2005]
1.4.3 Therapeutic applications of PNA anti-gene
The effectiveness of PNA anti-gene has been tested in different cell lines of 
neuroblastoma. Sun and colleagues have shown that these third-generation 
antisense conjugated to somatostatin analogs (SSA), are able to penetrate the 
nuclear area, to selectively inhibit the expression of MYCN in IMR-32 lines and 
stopping the growth. [Sun L. et al. 2002]
Other studies showed the inhibition of Eμ enhancer regions responsible of the 
over-expression of c-MYC  in Burkitt lymphoma lines (BL) [Cutron G. et al. 
2003], and the inhibition of c-MYC through PNA strategy in prostate carcinoma 
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cells. [Boffa L.C. et al. 2000] The inhibition usually leads to cellular cycle arrest 
and decrease of cell growth.
PNA conjugated to specific nuclear localization sequences (NLS) define the 
most evident effects in MYCN amplified neuroblastoma cell lines compared to 
not-amplified. 
These encouraging results obtained from in vitro studies must be followed by 
testing in vivo the PNAs.
1.5 Chemotherapy compounds
The chemotherapy drugs identify all those drugs whose chemical structure and 
physical properties are useful in the treatment against the majority of tumors.
They may be synthetic or produced by strains of microorganisms, show 
selective toxicity to infectious agents and cancer cells and absence (or reduced) 
toxicity to normal cells of human organism.
The chemotherapeutic agents cause cell death through different mechanism.. 
Anti-neoplastic agents are divided into specific categories based on their 
mechanism of action. In the following paragraphs we summarize features of two 
classes in particular: alkylating agents and inhibitors of topoisomerase II.
1.5.1 Alkylating agents
Alkylating agents can become strong electrophiles, thus interacting with 
nucleophilic groups (phosphate groups, amino, sulfhydryl, hydroxyl, carboxyl, 
imidazole) alkylating proteins and nucleic acids. Crucial importance has the 
cytotoxic effect related to the association of these drugs with DNA. The reaction 
that leads to the formation of stable drug-DNA complex (and / or protein) is 
schematically divided into two phases: 1) activation and 2) nucleophilic attack.
In the activation phase, cellular metabolic processes activate the alkylating 
agent to form an interim net positive charge. Once activated, the compound is 
able to interact with a number of groups which have a high electron density 
(phase nucleophilic attack).
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The main target of the alkylating agent is DNA; the chemical structure 
determines the degree of alkylation of various nucleophilic groups found in the 
nucleic acid molecule. In addition, both the structure and the charge of 
alkylating agents affect the specificity sequence of alkylation.
The alkylation of DNA bases leads to various physiological changes such as 
base-pairing errors and subsequent mutations during replication; chemical 
injury  and subsequent excision of bases, formation of covalent bonds within a 
filament and / or between filaments of DNA matched, stable ties with the 
associated proteins. Besides altering the functions of nucleic acids, the 
chemical alteration of cellular proteins leads to changes in different enzymatic 
functions, including those responsible for DNA repair.
These agents do not distinguish between cells into cell cycle and in quiescent 
cells (G0 phase), however, they are more toxic to rapidly proliferating cells. 
They are used to treat, in combination with other compounds, a wide variety of 
solid tumors and lymph.
Cisplatin and Carboplatin
Cisplatin and Carboplatin are platinum-based drugs that are widely used in 
cancer chemotherapy.
Cisplatin has a structure consisting of two labile ligands, two chlorides, and two 
inert binders, two amines; both in cis position. It acts interfering with all cell 
cycle phases binding the DNA. The most frequent bound is the intrastrand 
crosslink between two adjacent guanine. [Wang D. et al. 2005; Gonzales V.M. 
et al. 2001] 
Carboplatin has instead a motif CBDC (bidentate cyclobutane dicarboxylate), 
which gives more stability to the compound (Figure 5). It shares with cisplatin 
the same mechanism of action.
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Fig. 5 Structures of cisplatin and carboplatin.
Other interactions, however, have to be taken into consideration: mitochondrial 
DNA, actin (shift in composition), phospholipids and phosphatidylserine. The 
cross-link format involves a folding of the DNA, with exposure of the minor 
groove to the hooking of different proteins.
Cisplatin and Carboplatin are extremely  potent anti-neoplastic compounds and 
they are usually used in the treatment of small cell lung cancer, non-small cell 
lung cancer, ovarian cancer, metastatic testicular cancer in combination with 
bleomycin vinblast ine, and ovarian cancer in combination with 
cyclophosphamide. Cisplatin is the first line therapy for small cell lung cancer 
but can be substituted with carboplatin. Indeed, Carboplatin has less 
nephrotoxicity, neurotoxicity, ototoxicity and emetogenesis and more stability 
than cisplatin.
1.5.2 Topoisomerasi IIα inhibitor 
Etoposide (VP-16)
Etoposide is a semisynthetic derivate of the vegetal alkaloid podophyllotoxin 
responsible for inhibition of an essential enzyme for structural maintaining of 
DNA: mouse isomerase II α (α Topo2). It acts by forming a ternary complex 
DNA-drug Top2-α and disrupting the normal role of this enzyme on nucleic acid.
[Li TK. et al. 2001]
 
Fig.6 Etoposide structure.
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The drug inhibits the enzyme through steric hindrance (direct entry to the 
cleavage site that the enzyme has generated), triggering the following Fas-
FasL apoptotic cascade [Beck et al. 2001]. Its activity is directly  proportional to 
the concentration of ATP. 
Etoposide also involves inhibition of TopoisomeraseI through an indirect 
mechanism: the drug, binding to Top2 α, triggers the apoptotic cascade through 
deregulation of BCL-2, an important anti-apoptotic factor, hence activation of 
effector caspases (9-3), alteration of mitochondrial potential and the formation 
of toxic oxygen reactive inducing the block of Topoisomerase I. The blockade of 
this enzyme only requires further trigger the apoptotic cascade that amplifies 
the cytotoxic effect of the etoposide. [Sordet et al. 2004]
The drug is used as a chemotherapeutic agent, single or in combination with 
others, in various forms of cancer: Ewing's sarcoma, small cell lung cancer, 
testicular cancer, lymphoma, non-lymphocytic leukemia and glioblastoma 
multiform, and neuroblastoma. The most common adverse effects are: low 
blood pressure, alopecia, diarrhea, leukopenia and anemia.
1.6 Hedgehog pathway and Basal Cell Carcinoma
The Hedgehog signalling pathway regulates embryonic development and may 
be aberrantly  activated in a wide variety of human cancers [Wicking C. et al. 
2001]. Efforts to target pathogenic HH signalling have steadily progressed from 
the lab to the clinic, and the recent approval of the HH inhibitor Vismodegib for 
patients with advanced BCC represents an important milestone [Von Hoff DD. 
et al. 2009]. On the other hand, HH pathway antagonists have failed to show 
significant clinical activity in other solid tumours.
1.6.1 Hedgehog signalling pathway
The Hedgehog (HH) signalling pathway is required for the control of cell growth, 
proliferation and differentiation. The pathway is most active during 
embryogenesis but is also important for regulating the cell cycle in adult cells 
[Altaba A. et al. 2001; Beachy P. et al. 2004]. HH signalling is controlled by  the 
three HH ligands: Desert (DHH), Indian (IHH) and Sonic (SHH), which is most 
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relevant to skin. As SHH ligands bind to the PTCH1 transmembrane receptor, 
another transmembrane protein Smoothened (SMO) accumulates on the cell 
membrane where it is phosphorylated and activated [Denef N. et al 2000]. Upon 
activation, SMO causes the dissociation of Suppressor of Fused (SUFU), a 
negative regulator of the HH signalling pathway resulting in activation of GLI 
transcription factors, although it is unclear how the signal is transduced between 
SMO and SUFU (Figure 7). [Donovan J. et al 2009]
Of the three GLI transcription factors all are activators however, GLI-2 and 
GLI-3 can have repressive functions. GLI-1 is the most prominent of the three 
and its over expression has been observed in many different types of cancers.
[Ruiz i Altaba A. et al 2002]
Fig.7 The hedgehog signalling pathway
As a result of mutations of PTCH1 as seen in BCC, SMO is no longer repressed 
resulting in activation of the downstream signalling cascade. PTCH1 loss of 
heterozygosity or loss of function mutations have been observed in 30-70% of 
sporadic BCCs [Saran A. et al 2009]. Activating mutations have also been 
identified in SMO, although these are much less prevalent in BCCs. [Xie J. et al 
1998]
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The HH signalling cascade results in activation of the GLI transcription factors 
which are thought to increase cell proliferation and inhibit both differentiation 
and apoptosis. A positive feedback mechanism has been reported between 
GLI-1 and GLI-2 which implies that GLI-2 also plays a role in the formation of 
BCCs. GLI-2 was shown to activate proliferation in keratinocytes while 
repressing epidermal differentiation [Regl G. et al. 2002]. HH signalling has also 
been linked to Notch [Adolphe C. et al. 2006], TGF-β [Cretnik M. et al 2009] and 
Wnt/β-catenin pathways. [Adolphe C. et al. 2006]
 1.6.2 Basal cell carcinoma & Gorlin syndrome
Basal cell carcinoma (BCC) is the most common skin cancer in the world with 
BCCs accounting for 70% of all skin cancer [Mancuso M. et al. 2004]. BCC is 
the most common malignancy in Caucasians with approximately 3 in 10 
developing the disease within their lifetime and an annual increase in worldwide 
incidence of 10% [Crowson et al 2006]. The prevalence of BCC varies 
depending on geographical location where the incidence is greater in countries 
with greater sunlight exposure.
There are three subtypes of BCCs, identifiable by their histology: superficial, 
nodular and morpheic. Morpheic is the most aggressive and nodular the most 
common (Crowson, 2006) (Figure 8). Superficial BCCs appear as ulcers on the 
surface of the skin and histologically, they form a mass of cells below the 
epidermis. These extend from the dermis to the papillary dermis and have an 
increased risk of reoccurring if they are not fully removed (Saldanha et al., 
2003).
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Fig.8 BCC histology Histological section of [A] superficial, [B] nodular and [C] morpheic BCC 
(Crowson, 2006).
Although the majority of BCCs arise sporadically, several cases are attributable 
to the basal nevus syndrome, also known as Gorlin syndrome, an autosomal 
dominantly inherited disorder characterized by the occurrence of multiple BCCs 
and of extracutaneous tumors, that was first described by Professor Robert J 
Gorlin in 1960 [Gorlin RJ. at al. 1960]. Genetic studies on patients with BCNS 
have led to the identification of inactivating mutations located on chromosome 
9p22, specifically in the human homologue of the Drosophila gene Ptch1, as the 
genetic defect underlying this syndrome [Jonhson RL. et al. 1996; Hanh H. et al. 
1996]. The same loss of function mutations were found in sporadic BCCs from 
patients without BCNS [Gailani ME. et al. 1997]. The activation of Hedgehog 
signalling was then confirmed by the increased expression of the GLI-1 
transcription factor. [Ghali L. et al. 1999]
BCCs very rarely  metastasize but they are locally aggressive and 5-9% may 
have multiple recurrences [Marcil I. et al 2000]. Moreover they can cause 
significant scarring and disfigurement. This is mainly on the head or neck 
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however, it is potentially more damaging if located around the eyes. Surgery is 
curative for most patients; other common treatments include cryotherapy and 
radiotherapy while Imiquimod and photodynamic therapy (PDT) are more recent 
forms [Lien MH. et 2011]. Imiquimod based creams are applied to the tumour to 
cause an inflammatory response to destroy the lesion. 74% of patients reported 
complete remission of the tumours; however, this is only used to treat superficial 
BCCs. PDT involves applying a photosensitive drug to the tumour and upon 
activation of the drug by light, oxygen radicals are released that induce cell 
death with a cure rate reported to be 79%. However, for those few that develop 
locally advanced or metastatic BCC, there was no effective treatment. Then at 
the beginning of 2012, GDC-0449, a Genentech molecule, received the FDA 
approval. GDC-0449 is a SMO antagonist, that has shown a 50% response in 
metastatic tumours and 60% in advanced local tumours.
1.6.3 Ultraviolet radiation and Basal cell carcinoma
The p53 tumour suppressor gene plays an important role in cellular regulation. 
Its functions include cell cycle arrest, DNA damage repair and initiation of 
apoptosis. It is well documented that half of all BCCs have mutations of the 
TP53 gene [Soleti et al., 2009; Rady et al., 1992] with BCCs most commonly 
developing on sun exposed skin. The frequency of BCCs was shown to 
increase with patient age, which implies that longer exposure to UV light may 
cause mutations of p53. CC to TT or C to T transitions at di-pyrimidine sites of 
the p53 gene were found in UV exposed tumours resulting in the loss of 
function of the protein [Mancuso et al., 2004; D'Errico et al., 1997; Denef et al., 
2000; Zhang et al., 2001]. Due to this, the cells are unable to repair DNA 
damage caused by UV exposure and may not undergo apoptosis. Indeed, p53 
knockout mice have been shown to develop BBC-like tumours significantly 
earlier than wild type mice after UV irradiation.[Kim et al., 2002]
1.6.4 In vitro model of BCC
During my 10 months work experience at the Blizard Institute of Queen Mary 
University  in London I have assisted Dr.Muhammad M.Rahman to create an in 
vitro model of BCC by suppressing PTCH1 expression in human keratinocytes 
using RNAi; this model has been used to determine the extent and nature of HH 
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signalling in human BCC (including control of the GLI transcription factors) as 
well as to determine how PTCH1 interacts with other major signalling pathways, 
particularly those that may influence the formation and progression of this 
common skin tumour.
1.6.5 Role of MYCN in basal cell carcinoma
Studies on medulloblastoma, a primitive neuroectodermal childhood malignant 
brain tumour arising from cerebellar granule neuron precursors, identified 
NMYC as a direct target gene of the Shh pathway, suggesting that N-Myc 
protein is an important downstream mediator of Shh-induced proliferation and 
tumourigenesis.[Heine VM. et al. 2010]
In their work, Freier and colleagues performed immunohistochemistry  (IHC) and 
fluorescence in situ hybridisation (FISH) on 273 BCC specimens to assess the 
expression of N-Myc protein and gene copy numbers of the NMYC gene locus 
in a representative BCC tumour collection. High N-Myc protein expression was 
detected in 72.7% (160/220) of all BCC specimens. Strong N-Myc 
immunopositivity  was more frequently found in infiltrative BCCs compared to 
nodular/superficial BCCs (p=0.005), and in BCCs of the head compared to 
BCCs of other anatomic localizations (p=0.021). The prevalence of NMYC copy 
number gains was 17.5% (37/211), including three tumours with nodular 
differentiation that exhibited a distinct high-level amplification of the NMYC 
locus. These data indicate that high expression of the Shh downstream 
mediator, N-Myc, is a frequent event in BCC, predominantly in more aggressive 
subtypes. [Freier K. et al. 2005]
1.6.6 Targeting therapies in BCC
Half a dozen pharmaceutical companies have embarked on Hedgehog Inhibitor 
(HHI) development, and BCCs that are not curable by local therapies are 
potential targets for trials of HHIs. The leading molecule has been Cyclopamine 
[Binns et al. 1963]. Cyclopamine was discovered when pregnant sheep  that 
were eating the Veratrum californicum species of lily containing Cyclopamine, 
would carry embryos with holoprosencephaly (HPE). HPE is a developmental 
disorder where the midline of the face does not develop resulting in a cyclopic 
eye which has been linked to HH signalling as Cyclopamine was shown to 
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specifically inhibit SMO [Chen et al. 2002; Taipale J. et al. 2000]. SHH-/- 
knockout mice have also been reported to develop  HPE. Cyclopamine has been 
shown to inhibit human medulloblastoma growth which has led to the proposal 
for HH antagonists as a valid treatment however non-canonical HH signalling 
and the development of BCC through this mode of signalling has important 
therapeutic implications. Due to the low affinity of Cyclopamine, synthetic 
derivatives have been developed such as BMS-833923 (Bristol-Myers Squibb), 
CUR-61414, HhAntag-691, IPI-926, MK4101, SANT1, SANT4 and 
Cyclopamine- KAAD.
The most encouraging results have been achieved by using the Genetech 
compound GDC-0449 Vismodegib, trade name ERIVEDGE. This compound 
has been approved by FDA in January 2012 after a phase II trial (Erivance 
BCC) conducted to fully evaluate the efficacy and safety  of Vismodegib  in 
patients with locally advanced or metastatic Basal cell carcinoma. In 33 patients 
with metastatic BCC, the independently assessed response rate was 30% (95% 
confidence interval [CI], 16 to 48; P=0.001). In 63 patients with locally  advanced 
basal-cell carcinoma, the independently assessed response rate was 43% (95% 
CI, 31 to 56; P<0.001), with complete responses in 13 patients (21%). The 
median duration of response was 7.6 months in both cohorts. [Van Hoff D.D. et 
al . 2008; Tang YJ. et al. 2012]
The drug is also undergoing clinical trials for metastatic colonrectal cancer, 
small cell lung cancer, advanced stomach cancer, pancreatic cancer, 
medulloblastoma and chondrosarcoma.
The targeting of other HH components such as GLI with GANT58 and GANT61 
are undergoing various phases of development.
1.6.7 EGFR signaling pathway in Basal cell carcinoma
Several studies suggest that HH can cooperate with EGFR signalling as the 
over expression of SHH in HaCaT immortalized keratinocytes that were grown 
in organotypic culture, induced a basal phenotype and promoted invasion of the 
cells into the collagen matrix. SHH expression was shown to increase the 
phosphorylation of EGFR, JNK and Raf as well as increase Matrix 
Metalloproteinase-9 (MMP-9) which has been implicated in cell invasion and 
tumour aggression. [Tai et al., 2008]
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The epidermal growth factor receptor (EGFR) is the cell-surface receptor for 
members of the epidermal growth-factor family (EGF-family) of extracellular 
protein ligands [Herbst RS. et al. 2004]. Mutations affecting EGFR expression 
or activity could result in cancer.[Zhang H, et al. 2007].
Epidermal growth factor and its receptor was discovered by Stanley Cohen of 
Vanderbilt University. Cohen shared the 1986 Nobel Prize in Medicine with Rita 
Levi-Montalcini for their discovery of growth factors.
The binding activates several pathways principally  the MAPK, Akt and JNK 
pathways, leading to DNA synthesis and cell proliferation [Oda K. et al. 2005]. 
Such proteins modulate phenotypes such as cell migration, adhesion and 
proliferation. Activation of the receptor is important for the innate immune 
response in human skin.
Studies have shown that EGFR signalling modulates the expression of GLI 
target genes in N/Tert human immortalised keratinocytes [Kasper et al., 2006]. 
19 genes were found to be induced synergistically  by  GLI1 and EGF treatment 
also; GLI1 target genes were shown to be modulated by EGFR signalling 
through MEK/ERK pathways.
Studies have also identified that HH and EGFR synergy can induce oncogenic 
transformation which is mediated through EGFR activation of RAS/RAF/MEK/
ERK. EGFR/MEK/ERK pathways are able to induce JUN signalling which is 
essential for oncogenic transformation. EGFR/MEK/ERK pathways also 
increase GLI1 and GLI2 expression. In mouse cells where BCCs develop  as a 
result of activated HH signalling, inhibiting both EGFR and GLI signalling shows 
a reduction of BCC growth and therefore presents a potential therapeutic 
opportunity [Schnidar et al. 2009].
In contrast, Neill group has previously shown that the over expression of GLI1 in 
N/Tert cells reduces EGFR expression and that compact colony formation (a 
characteristic of BCC tumour formation) is associated with repressed ERK 
activity  [Neill et al., 2008]. Lately we performed staining of a panel of BCCs that 
revealed no pERK expression in 13/14 tumours whereas pERK was expressed 
in the epidermis suggesting that its loss is important for tumour formation.
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1.6.8 Role of HH pathway in SCLC
In 2009 BMS started a clinical trial to determine the maximum tolerated dose 
(MTD) of BMS-833923 administered in combination with carboplatin and 
etoposide followed by BMS-833923 alone in subjects with extensive-stage 
Small Cell Lung Cancer (SCLC). The trial is still ongoing [Tang JY. et al. 2012] 
There are infact several scientific evidences of HH involvement in SCLC. Park 
and colleagues found that Hedgehog is activated in SCLC cells independently 
of the lung microenviroment. They found that treatment with Cyclopamine, a 
Smo inhibitor, decreased the survival of SCLC cells in low serum and also 
decreased GLI1 mRNA levels. [Park KS. et al. 2011]
1.7 Murine models
Animal models of cancer provide an alternative means to determine the causes 
of and treatments for malignancy, thus representing a resource of immense 
potential for cancer medicine. The models described here identify  what is the 
next step after an in vitro testing and the analysis of a molecule in a biological 
system more complex than cellular, more human-like. 
The mouse (mus musculus) is among the most used species for preclinical 
studies; this is mainly  due to its size, lifelenght, molecular and physiological 
similarities with man.[Frese KK. et al 2007]
1.7.1 Tumor xenograft models
The xenograft model is obtained through the injection of tumor cells in nude 
mouse and Severe Combined Immunodeficiency (SCID) mouse: these animals 
have deficits in the immune system and mainly in the lymphoid component. 
Nude mouse does not present thymus and for this reason is immunodeficiency 
in T-lymphoid cell and presents total loss of hair; the SCID mice present genetic 
alterations, these are reflected in lack of lymphoid B cells, T cells and natural 
killer cells (NK).
The term xeno means "external", infact it involves transplantation of cells, 
tissues or organs between different species of living beings. This technique 
differs from allo-transplantation, where donor and recipient belong to the same 
species.
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Xenograft models can be divided into: 1)Ectotopic xenograft models and 
2)Orthotopic xenograft models. In the ectotopic model transplant is made under 
the skin; in the orthotopic, instead, transplantation is in the same anatomical 
location where usually the tumor arises.
The orthotopic is largely considered more predictive of the clinical outcome. 
Studies are, indeed, closest to those observed in a clinical, vastly reducing false 
positives associated with an experimental drug. Moreover they are less 
expensive than transgenic models, with lower latency and suitable for all types 
of cancer. [Killion KK. et al 1999; Sharpless NE. et al. 2006]
1.7.2 Transgenic mouse models
The term transgenic was coined in 1981 by Gordon and Ruddle to describe an 
animal whose genome is introduced into an exogenous gene; in the 80s the 
term was extended to the experiments of “gene-targeting", a method used to 
insert genes into specific points of the genome and production of chimeric and 
knockout mice, in which one or more genes are selectively removed from the 
genome. Today transgenic animals are called the animals that have undergone 
any type of genetic specific modification. 
The use of transgenic mice to study specific genes that cause the onset of 
determinate cancers is the best approach in spite of the use of xenograft 
animals. This choice depends by  several reasons: the similarity  of the 
histological tumor; the tumor is not usually  immunogenic, but it develops in a 
immunocompetent mouse; the tumor develops spontaneous, and also it can 
present metastasis; it is possible to study a wide range of cancers.
SCLC transgenic mouse model
It has been very challenging to create a transgenic mouse model of SCLC. The 
issues were the cell of origin and its neuroendocrine features and several 
aberrational genetic patterns that are involved in this tumor.
So far Berns and colleagues created the best suitable mouse model of SCLC 
starting from the findings that high mutation frequencies of tumor suppressor 
genes Rb1 and Trp53 have been observed in human SCLCs. Introduction of 
both Rb1 and Trp53 lesions into pulmonary epithelial cells via mouse germ line 
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mutations is precluded by the embryonic lethality of Rb1 null mutants. They 
therefore decided to use the Cre-loxP system for introducing Rb1 and Trp53 
mutations somatically in a broad range of lung epithelial cells. In a relative short 
time-span after lung epithelial cells were infected with Adeno-Cre virus [Lyons 
SK. et al. 2003], they observed small foci of NE cell proliferation in airways, and 
in these, both alleles of Rb1 and Trp53 were inactivated. These lesions 
progressed to dysplasia and histologically  malignant lung tumors, displaying NE 
differentiation and SCLC morphology. These tumors, accordingly designated 
mouse small cell lung carcinomas (MSCLCs), were highly proliferative, invasive, 
and had a marked capacity to metastasize to liver, brain, adrenal gland, bone, 
and ovaries. Taken together, histopathology, immunophenotype, and patterns of 
growth and dissemination of MSCLC are indeed strikingly similar to human 
SCLC.[Meuwissen et al. 2001; Berns A. et al. 2005]
BCC mouse model
The identification of the pivotal role of HH signalling in BCC carcinogenesis 
stimulated the engineering of several models in which HH signalling could be 
manipulated and BCCs could be produced, some of which carry  inactivating 
mutations in genes encoding inhibitors of HH signalling, and some of which 
carry  activated mutants or overexpressed wild-type positive regulators of this 
pathway. These models have allowed studies of interventions — 
chemoprevention and chemotherapy — as well as more basic investigations 
into BCC tumorigenesis.
The first lesson derived from the models is that deregulated HH signalling is 
indeed crucial to BCC carcinogenesis. Thus, either constitutive or conditional 
overexpression of GlI1 [Nilsson M. et al. 2000] or of GlI2 [Grachtchouk M. et al. 
2000] in keratinocytes can produce BCC-like proliferations in the skin. Similarly, 
expression of SMO carrying the activating mutations identified in human BCCs 
also can produce murine BCCs [Xie J. et al. 1999]. Furthermore, Ptch1+/– mice 
develop BCCs, and those BCCs often have deletion of the wild-type copy of 
Ptch1 as well as upregulation of HH signalling [Aszterbaum M. et al. 1999]. 
Similarly, mice carrying one inactivated, mutant allele of the HH suppressor 
Sufu are also susceptible to BCC development [Svard, J. et al.2006]. Thus, 
mice carrying mutations in genes that encode at least four different components 
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of the HH signalling machinery  develop BCCs, or at least skin tumours 
resembling BCCs.
Another lesson is that it seems that the degree of activation of HH signalling is 
correlated with the histological appearance — the stronger the activation, the 
more the tumours resemble human BCCs [Grachtchouk, V. et al. 2003].
As already  reported, p53 loss of function is frequently found in human BCCs 
and in murine BCC-like lesions. This was shown first by  the development of 
medulloblastomas in almost 100% of Ptch1+/–;Trp53–/– mice as opposed to an 
incidence of less than 10% in Ptch1+/– mice that have wild-type p53 [Wetmore 
C. et al. 2001]. Similarly, Epstein and coll. found that Ptch1+/– mice in which p53 
is deleted conditionally in K14-expressing keratinocytes have a marked 
enhancement of BCC carcinogenesis [Aszterbaum M. et al. 1999]. Therefore, 
the high incidence of p53 mutations in human BCCs is probably not simply 
caused by the fact that BCCs usually arise in sun-exposed skin, but rather 
reflects the ability  of p53 loss to contribute to the development of BCCs and 
perhaps to that of other HH-driven tumours as well.
Finally, results of pharmacological interventions in the Ptch1+/– mouse seem so 
far to correlate well with results of the same interventions in humans. For 
example, topical application of the retinoid tazarotene, a retinoic acid receptor-
β/γ ligand that is widely used for treatment of acne, (see later) inhibits BCC 
development in the Ptch1+/– mouse and has clear anti-BCC efficacy in humans. 
Similarly, we have found that systemic non-steroidal anti-inflammatory drugs, 
such as celecoxib, weakly inhibit BCC  carcinogenesis in both human and 
mouse PTCH1+/– individuals.
Table 2 Occurrence of basal cell carcinoma (BCC) in mouse models
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For our immunohistochemical analysis, in particular, we have used tissues from 
mice lacking one Ptc1 allele (Ptc1neo67/+), derived by  gene targeting of 129Sv 
embryonic stem cells and maintained on the outbred CD1 strain background, X-
ray irradiated at the estimated time of the second anagen, active growth phase 
of hair follicles, [i.e., 35 days (n = 60)] or of the second telogen, resting phase of 
hair follicles, [i.e., 60 days (n = 56)]. [Mancuso M. et al al. 2004]
1.8 Molecular imaging
Bioluminescence imaging (BLI) is increasingly  being used to provide 
quantitative and more rapid assessment of drug efficacy in preclinical oncology 
research. BLI of firefly luciferase (Photinus pyralis; FLuc) activity provides a 
cost-effective and extremely sensitive method for imaging fundamental 
biological processes in vitro and in vivo [6-8]. In vivo BLI is an excellent method 
to gain a dynamic, longitudinal profile of engraftment. Luciferase oxidizes 
luciferin in the presence of adenosine tri-phosphate (ATP) and oxygen to form 
an electronically  excited oxy-luciferin species. Visible light is emitted following 
the relaxation of excited oxy-luciferin to its ground state [Sadikot R. et al. 2005]. 
Because this light can be transmitted through mammalian tissues, it is possible 
to use bioluminescence for non invasive and quantitative monitoring of tumors 
burden.
In nature there are different bioluminescent systems characterized by a specific 
enzyme system. The most used bioluminescent system in scientific research is 
the North American firefly luciferase , but several clones of luciferase were 
identified from jellyfish (Aequorea), from the sea pansy (Renilla), from corals 
(Tenille) and from various bacteria as Vibrio fischeri and V. harveyi.
Luciferase is an excellent marker for gene expression because it lacks post-
translational modifications and has a half-life (t 1/2) in vivo of about 3 hours.
The spectrum of light is between 530 and 640 nm with an emission peak at 562 
nm. This emission spectrum, coupled to the optical properties of tissue, allows 
light to penetrate through several centimeters of tissue. In this way  it is possible 
to detect light emitted from the internal organs of small mammals that express 
the luciferase as reporter gene. The photons are detected by a special Charge 
Coupled Device (CCD) camera that convert photons into electrons. The CCD 
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camera spatially encoding the intensity of the incident photons into electrical 
charge patterns to generate an image. This camera is controlled by a computer 
for image acquisition and analysis.
The BLI is widely used in cancer research for identifying metastasis and to 
measure the proliferation of tumor cells that express luciferase. Some studies 
done using HeLa luminescent cells injected into the tail vein of immunodeficient 
mice have demonstrated the utility of BLI in the early detection of lung 
metastases. Similarly, other studies have shown that bioluminescence is a 
powerful methodology for understanding the pathogenesis of the disease in 
vivo. It has been shown that the detection of tumor cells in internal organs by 
BLI has a sensitivity at least equal to that of positron emission tomography 
(PET). Moreover BLI does not require toxic and radioactive tracers, only 
administration of D-luciferin, non-toxic even in newborn pups. [Doholen G. et al. 
2008]
1.8.1 Transfection of cell lines throughout retroviral vectors
Recombined retroviruses have been widely used to obtain stable expression of 
heterologous genes in the mammalian cells. The most commonly studied and 
used retroviruses are those belonging to the Retroviriade subclass. This 
retrovirus typology is modified and it has lost its replicative capacity because it 
does not present some genes express within the wild type strain. They allow the 
stable integration of transgenes within the eukaryotic cells genome. [Blesh A. et 
al. 2003]
Retroviruses are viruses whose genome consists in a single-stranded RNA of 
around 10 Kb  of size with a region ψ for the packaging. It includes three 
essential genes, gal, pol, envelope. They  codify  respectively for the core 
proteins, the inverse transcriptase and the capside.
Long Terminal Repeats (LTR) are placed to each edges and these sequences 
are implied in the integration phase. LTRs are divided in three regions: U3, R 
and U5. The 5’ R is defined as the initial signal sequence for the transcription 
phase in the 5' LTR, whereas the U3 region contains both the promoter and the 
enhancer element. Moreover, the U3 region contains the signal of 
poliadenilation. During the retro-transcription, the U3 region at the 3' LTR and 
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the U5 region at the 5' LTR of the viral RNA are duplicated (Figure 9). Once the 
cell is infected, the RNA is retro-transcribed in a double DNA filament that 
entries in the nucleus and it is integrated in the genome of the host cell, 
expressing in this way the viral proteins. Simple retroviruses such as MLV are 
unable to cross the nuclear membrane and the infection is restricted to cells in 
mitosis, when the nuclear membrane is dissolving.
Fig.9 Life cycle of retrovirus.
The most common retroviral vectors are derived from MLV (Moloney Murine 
Leukaemia Virus), an amphotropic virus able to infect both human and murine 
cells.
In these vectors, viral genes are replaced by  the transgene of interest, which is 
inserted between the LTRS downstream packaging signal and the promoter. 
They can also be added with marker genes (such as neomycin) and alternative 
promoters of viral origin.
The gag, pol and env coding regions are separated into distinct transcriptional 
units to decrease the risk of production of wild-type virus through recombination, 
and added to cell lines that are called packaging cells. The packaging cells are 
able to generate a complete virion, but empty because they do not contain the 
sequence ψ and cannot package the viral genome in the virion. The viral vector 
instead contains the transgene downstream of ψ, and thus, if inserted into a 
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packaging line, it produces a viral progeny which virion is provided by the 
packaging line and the genome is the recombinant viral vector containing the 
transgene .
The range of cells that can be infected by recombinant retroviruses thus 
produced, depends on the type of envelope protein in the virion. We can 
distinguish ectotropics retrovirus, which can only infect cells of rodents and 
anfotropics retrovirus, which infects almost all mammalian cells.
The choice of vector system is highly dependent on target cells. Generally, 
vectors derived from MLV are easier to produce and, to date, are available in a 
wide range of packaging cells. However, infection by these viruses is extremely 
low in quiescent cells or low growth rate and therefore should be used only in 
cells with high growth rates such as tumor cells.
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CHAPTER 2
AIM OF THE STUDY
Human small cell lung cancer (SCLC) accounting for approximately 15-20% of 
all lung cancers, is an aggressive tumor with high propensity for early regional 
and distant metastases. Chemotherapy is the primary treatment option, leading 
to a 5 year survival of approximately 20% in LD and less than 5% in ED. 
Although the initial tumor rate response to chemotherapy is very high, SCLC 
relapses after approximately 4 months in ED and 12 months in LD.
Basal cell carcinoma (BCC) is the most prevalent cancer in the Western world, 
and its incidence is increasing worldwide. This type of cancer rarely 
metastasizes and the death rate is extraordinary low. Surgery is curative for 
most of the patients, but for those that develop  locally advanced or metastatic 
BCC there is currently no effective treatment. Moreover surgery is expensive, in 
total the cost of care for non-melanoma skin cancers is the fifth highest for all 
cancers in US.
Both types of cancer have been deeply investigated and several genetic 
alterations have been found. These alterations could become targets for new 
pharmacological therapies.
New drug must be investigated through preclinical and clinical studies. 
Especially, prediction of human tumor response based on preclinical data could 
reduce the failure rates of subsequent new anticancer drugs clinical 
development. 
Therefore, the aims of the study were the following:
1- To create and characterize a novel BLI xenograft orthotopic mouse model of 
SCLC to evaluate the tumor onset and progression and the efficacy of new 
pharmacological strategies.
2- To compare an in vitro model with a transgenic mouse model of BCC  and to 
investigate and delineate the canonical Hedgehog signaling pathway and its 
connections with other molecular pathways. Thus may lead to potential new 
therapies, less invasive than surgery.
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CHAPTER 3
MATERIALS AND METHODS
3.1 Small cell lung cancer
3.1.1 Cell lines
In Table 1, all the SCLC cell lines that have been characterized for MYC family 
genes. After this characterization the most representative have been chosen for 
in vitro proliferation assays, chemotherapeutic treatments and orthotopic mouse 
model.
Three of the members of the MYC family, MYC, NMYC and LMYC, have been 
shown to be amplified in tumors and tumor cell lines from patients with small 
cell lung cancer.[Johnson BE. et al. 1996]
CELL LINE MEDIUM CHARACTERISTICS
H69
RPMI 1640 + FBS 10%, 
L-glutammin 1% and 
antibiotics, penicillin and 
streptomycin 1%
Small round cells growing in medium-
large aggregates.
Source: Lungs
Expression of myb, fes, fms, raf, ras 
mRNA
c-met and p53 mutations
H526
RPMI 1640 + FBS 10%, 
L-glutammin 1% and 
antibiotics, penicillin and 
streptomycin 1%
Small round cells growing in medium-
large aggregates.
Source: Lungs
Expression of myb, fes, fms, raf, ras and c-
kit mRNA
N592
RPMI 1640 + FBS 10%, 
L-glutammin 1% and 
antibiotics, penicillin and 
streptomycin 1%
Small round cells growing in medium-
large aggregates.
GLC14
RPMI 1640 + FBS 10%, 
L-glutammin 1% and 
antibiotics, penicillin and 
streptomycin 1%
Small round cells growing in aggregates.
Source: Supraclavicular node biopsy 
before the start of chemotherapy
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H378
RPMI 1640 + FBS 10%, 
L-glutammin 1% and 
antibiotics, penicillin and 
streptomycin 1%
Small round cells growing in aggregates.
Source: metastatic site, pleural effusion.
H1618
HITES + FBS 10%, L-
glutammin 1% and 
antibiotics, penicillin and 
streptomycin 1%
Small round cells growing in aggregates.
Source: metastatic site, bone marrow.
H510
RPMI 1640 + FBS 10%, 
L-glutammin 1% and 
antibiotics, penicillin and 
streptomycin 1%
Small round cells growing in aggregates.
H510A
RPMI 1640 + Ham’s F12 
(1:1) + FBS 10%, L-
glutammin 1% and 
antibiotics, penicillin and 
streptomycin 1%
Adherent cells.
Source: metastatic site, adrenal gland.
H82
RPMI 1640 (w/o 
phenolred) + FBS 10%, 
L-glutammin 1% and 
antibiotics, penicillin and 
streptomycin 1%
Small round cells growing in medium-
large aggregates.
DMS-79
RPMI 1640 + FBS 10%, 
L-glutammin 1% and 
antibiotics, penicillin and 
streptomycin 1%
Small round cells growing in medium-
large aggregates.
Expression of v-fes, c-raf1, H-ras, K-ras 
and N-ras, and SHH proteins.
After treatment they produce ectopic 
ACTH.
H146
RPMI 1640 + FBS 10%, 
L-glutammin 1% and 
antibiotics, penicillin and 
streptomycin 1%
Small round cells growing in medium-
large aggregates.
Expression of myc, myb, fms, raf, ras
GLC16
RPMI 1640 + FBS 10%, 
L-glutammin 1% and 
antibiotics, penicillin and 
streptomycin 1%
Small round cells growing in medium-
large aggregates.
Source: Supraclavicular node biopsy after 
chemotherapy
GLC19
RPMI 1640 + FBS 10%, 
L-glutammin 1% and 
antibiotics, penicillin and 
streptomycin 1%
Small round cells growing in medium-
large aggregates.
Source: Supraclavicular node biopsy after 
second reinduction therapy for relapsed 
SCLC
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Cell lines were subcultured at 37°C / 5% CO2 weekly.
The generation of luciferase positive SCLC-cell lines required Phoenix cell line 
(Phoenix Retroviral Expression System, Orbigen). Cell culture was maintained 
in DMEM medium (SIGMA-ALDRICH, Milwakee, WI) supplemented with 10% 
FBS (Euroclone, Pero, Milano, Italy), 1% L-glutamine 2mM (GIBCO-Invitrogen, 
Carlsbad, CA), 1% streptomycin/penicillin antibiotics (GIBCO-Invitrogen, 
Carlsbad, CA).
3.1.2 RNA isolation and gene expression analysis
Total RNA was extracted from 2x106 SCLC  cell lines and from 30 mg of frozen 
tissues according RNAspin Mini RNA Isolation Kit (GE Healthcare, UK): after 
homogenization, add 350 μl Buffer RA1 and 3.5 μl β-mercapto-ethanol to the 
samples. To clear the lysate filter it with a RNAspin Mini Filter unit. Centrifuge 1 
min at 11000 x g, add 350 μl 70% ethanol, mix the samples and load them into 
a RNAspin Mini column. After 30 sec at 8000 x g, add 350 μl Membrane 
Desalting Buffer, centrifuge for 1 min at 11000 x g to dry the membrane. 
Centrifuge for 1 min at 11000 x g, digest DNA with 95 μl of DNase reaction 
mixture, incubate for 15 min at room temperature. Wash the membrane with 
200 μl Buffer RA2, centrifuge 11000 x g for 1min, add 600 μl Buffer RA3, 
centrifuge 11000 x g for 1 min, add 250 μl Buffer RA3, centrifuge 11000 x g for 2 
min. Elute the RNA in 40 μl H2O RNase–free. Each RNA sample was quantified 
twice with the NanoDrop ND-1000 spectrophotometer (NanoDrop  Technologies, 
Wilmingon, DE). The 2 μg RNA (final volume of 10 μl) was reverse transcribed 
using Superscript II RNAseH (Invitrogen): add 1 μl dNTP 10 mM and 1 μl oligo 
dT to 10 μl of sample, incubate the mix for 5 min at 65°C and for 1 min in ice. 
Add 4 μl Buffer 5x, 2 μl DTT 0.1M, 1 μl RNase OUT to the sample, incubate at 
42°C for 2 min, add 1 μl of Superscript II (50U), incubate at 42°C for 50 min and 
at 70°C for 15 min. Quantitative PCR analysis was performed to confirm MYCN 
over expression and to analyse the efficacy of the PNA treatments. We used 
LightCycler® 480 Roche, according to the manufacture’s instruction and SYBR 
Green I Master (Roche Applied Science, Mannheim, Germany). The real-time 
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quantitative PCR was performed added to 10 ng cDNA (4 μl final volume), 10 μl 
Fast Star SYBRGreen MasterMix 2x (Roche), 0.6 μl primers forward and 
reverse 10 nM and water to final reaction volume of 20 μl. PCR reaction 
conditions were 2 min at 50°C, 10 min at 95°C, for 50 cycles: 15 sec at 95°C, 
60 sec at 60°C. Each sample was amplified in triplicate. ∆∆Ct calculations were 
used to determine the level of expression of target genes relative to reference 
control and to a calibrator (untreated samples or normal tissue).
The primer sequences for analyse MYCN over expression in SCLC tumors, 
SCLC cell lines and to test the efficacy of PNA treatment are: 
- MYCN forward: 5’-CGA CCA CAA GGC CCT CAG T-3’
- MYCN reverse: 5’-TGA CCA CGT CGA TTT CTT CCT-3’
- MYC forward: 5’-CAC CTG AGA CTG AAA CCG TAC AA-3’
- MYC reverse: 5’-CTT CTG CAA ATC TGG ATG GC-3’
- MYCL forward: 5’-CAA GCG ACT CGG AGA ATG AA-3’
- MYCL reverse: 5’-GCA TGG AGA TGT GGA AAT GCT T-3’ 
- ATPs forward: 5’-TCA CCC ACA CTG TGC CCA TCT ACG A-3’
- ATPs reverse: 5’-CAG CGG AAC CGC TCA TTG CCA ATG G-3’
- β-ACT forward: 5’-TCA CCC ACA CTG TGC CCA TCT ACG A-3’
- β-ACT reverse: 5’-CAG CGG AAG CGC TCA TTG CCA ATG G-3’
3.1.3 Protein extraction
The N-myc protein was assessed in total protein extracts. The total proteins 
were extracted resuspending the pellet of cells or homogenized tissues in RIPA 
buffer (ROCHE) lysing solution added with 4 Protease Inhibitors (Aprotinin, 
Leupeptine, Phenylmethanesulfonyl fluoride, Sodium Orthovanadate SIGMA) in 
a 1:200 rate. con l’aggiunta di quattro inibitori delle proteasi in rapporto 1:200. 
After 10 min of incubation on ice, the sample was centrifuged at 15000 x g for 3 
min at 4°C and the supernatant was collected containing total cellular proteins.
Protein were quantified with BCA method [Smith PK. et al. 1985] and the 
standard curve was constructed using known amounts of BSA protein (Bovine 
Serum albumin), by NanoDrop  ND-1000 spectrophotometer (NanoDrop 
Technologies, Wilmingon, DE).
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3.1.4 Western Blot analysis
Proteins were separated by one-dimensional gel electrophoresis in denaturing 
conditions (SDS-PAGE: Sodium Dodecyl Sulphate - Polyacrylamide Gel 
Electrophore). The samples, containing 100 micrograms of proteins were 
solubilized by incubation at 95°C for 5 min after the addition of 2X Laemmli 
sample buffer (125 mM Tris pH 7, 4% SDS, 20% glycerol, 10% β-
mercaptoethanol and bromophenol blue 0.004%) and water to a volume of 
about 20 ml. Following the preparation of Separating gel 7-10% (7-10% 
acrylamide, 375 mM Tris pH 8.8, 0.1% SDS, 0.1% APS, TEMED 0.1%) and 4% 
stacking gel (4% acrylamide, 125 mM Tris pH 6.8, 0.1% SDS, 0.1% APS, 
TEMED 0.1%), the samples were loaded in gel electrophoresis and run at 160 
V for about 60-90 min in electrophoresis buffer (125 mM Tris, 0.96 M glycine 
and 0.5% SDS) with a molecular weight marker, SeeBlue Plus2 Pre-Stained 
Standard (Invitrogen).
Proteins were separated by SDS-PAGE and they were transferred to PVDF 
membrane (polyvinylidene fluoride, Hybond-P, Amersham Biosciences) by 
western blot using the Bio-Rad wet system (Mini Trans-Blot Cell). The 
membrane was activated in methanol for 10 sec and then rebalanced in water 
for 5 min. Sponges and filters, before use, were soaked in transfer buffer (25 
mM Tris, 192 mM glycine, methanol 10%), and then were assembled filter-
sponge-gel-membrane-filter-sponge and the transfer was performed in transfer 
buffer at 250 mA for 2 hours. The membrane was subjected to successive 
incubation of 1 hour at room temperature with blocking solution (PBS, Tween 
0.2% and 5% milk), and subsequential over-night incubation with the primary 
antibody: mouse monoclonal N-myc IgG (NCM II 100, Calbiochem) or mouse 
monoclonal βß-actin (Calbiochem). After 3 washes in PBS and Tween 0.2%, 
incubated with corresponding secondary antibody Sheep anti-mouse IgG-HRP 
(horseradish peroxidase) ) (Amersham Biosciences). All antibodies were diluted 
in PBS+Tween 0.2% and 3.5% BSA (1:200 N-Myc and 1:10000 N-Myc anti-
mouse).
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The membrane was washed 3 times in PBS and 0.2% Tween for 5 min and was 
incubated for 1-2 min in the dark with the ECL detection solution (Amersham 
Biosciences). The survey was carried out to ChemiDoc (Biorad), using the 
program QuantityOne.
3.1.5 Fluorescence In Situ Hibridization (FISH)
FISH analysis was performed on fixed SCLC cells and on paraffin embedded 
tissue to confirm MYCN amplification. The tissue slides were treated with 
Paraffin Pre Treatment Kit from Abbott Molecular Inc (Des Plaines IL 60018 
USA) and FISH analysis was performed according to the protocols 
recommended by  the manufacturer (Vysis Inc., Downers Grove, IL, USA). 
Specific locus probe for MYCN (LSI-N-MYC(2p24), Vysis) and centromeric 
probe for chromosome 2 (CEP2(2p11.1-q11.1), Vysis) were used. Hybridization 
signals were analysed on a Olympus BX51 microscope coupled to a Cytovision 
Ultra system (Applied Imaging, Sunderland, UK).
3.1.6 In vitro treatment
To assess the cytotoxic and proliferative effects of chemotherapeutic drugs, on 
H69, H526 and GLC14 cell lines, at 72 hours, I used the Adenosine 
TriPhosphate monitoring system based on firefly (Photinus pyralis) luciferase 
(ATPliteTM Perkin Elmer, Waltham, MA, USA). The experiments were 
performed on 96-well microplate adding 50 μl of mammalian cell lysis solution 
to a 100 μl cell suspension. After 5 min in an orbital shaker at 700 rpm, I added 
substrate solution containing luciferase and D-luciferin. After 5 min in an orbital 
shaker and 10 min at dark the emitted light was measured with Infinite F200, 
TECAN. The measured luminescence is proportional to the ATP concentration. 
ATP is a marker for cell viability  because it is present in all metabolically active 
cells and the concentration declines rapidly when the cells undergo necrosis or 
apoptosis. (ATPLT-0408 / REV. F). Each experiment was performed at least four 
times. The concentration range used is shown in the table below.
Stock solutions[µM] Range [µM]
Cisplatin (CDDP) 3300 400 – 200 – 100 – 50 – 25 
Carboplatin (CBDCA) 2690 600 – 300 – 150 – 75 – 37,5
Etoposide (VP-16) 33900 140 – 70 – 35 – 17,5 – 8,75
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After this, we performed new experiments to obtain the EC50 for each drug. 
The diluitions range this time was: 
H69 N592 GLC14
CDDP
40 µM
4 µM
0,4 µM
0,0004 µM
0,000004 µM
400 µM
200 µM
100 µM
50 µM
25 µM
400 µM
200 µM
100 µM
50 µM
25 µM
CBDCA
600 µM
300 µM
150 µM
75 µM
37,5 µM
600 µM
300 µM
150 µM
75 µM
37,5 µM
18,75 µM
600 µM
300 µM
150 µM
75 µM
37,5 µM
VP-16
140 µM
70 µM
35 µM
17,5 µM
8,75 µM
140 µM
70 µM
2,8 µM
0,028 µM
0,00028 µM
0,000028 µM
140 µM
70 µM
35 µM
17,5 µM
8,75 µM
Cisplatin/Etoposide combination treatment
Cisplatin in combination with etoposide is now considered to be the standard 
first-line treatment of SCLC. The main goal is to achieve better results with 
lower doses of the two drugs and to improve their toxicological profile.
After the EC50 evaluation of each drug we performed a combination experiment 
using H69 cell line treated with CDDP and VP-16 at the same time.
EC50 1/2 of each drug has been added and citotoxic effect evaluated via 
ATPlite.
3.1.7 PNA treatment
The PNA was designed as homologous to a unique sequence of the noncoding 
(antisense) strand in exon 2 of MYCN (bp 1,650-1,665: 5‘-ATGCCGGGCATG 
ATCT-3’; Genbank accession no. M13241). This PNA antigene (PNAs), which is 
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complementary to a unique sequence in the DNA strand, was designed to 
directly inhibit mRNA synthesis. To test the specificity of the activity of this 
PNAs, a mismatched PNA (PNAmt) was also designed containing a 3-base 
substitution (5’-GTGCCGAGCATGGTCT-3’). Specificity was verified using the 
BLAST homology program. All the PNA molecules were covalently linked to 
their COOH terminus with a nuclear localization signal (NLS) peptide 
(PKKKRKV) to mediate transfer across the nuclear membrane [Tonelli R. et al . 
2005]. Synthesis, purification and characterisation of the PNAs and PNAmt was 
made by our laboratory as described.[Pession A. et al. 2004]
PNAs-NLS was added at concentrations of 2.5, 5, 10 μM on H69 cell line 
growth in Optimem added with 0.25% of FBS. Cells were harvested and 
analysed at 24, 48 and 72 hours after treatment.
3.1.8 Generation of luciferase-positive SCLC cell lines
The pMMP-LucNeo vector (Figure 10), a generous gift from Prof. A. Kung 
(Harvard University, Boston) was used to transform in XL1 E.coli competent 
cells (Agilent Technologies, Stratagene, La Jolla, CA).
Fig.10 pMMP-LucNeo vector
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One microgram of plasmid DNA was used to transform E. coli with heat shock 
at 42°C  for 30 sec, bacteria were grown overnight at 37°C in LB medium 
composed of 5 g bacto-yeast extract, 10 g bacto-tryptone, 10 g NaCl, 1 ml 
ampiciline 1 mg/ml and 1 l water. The plasmid DNA was extracted and purified 
with QIAfilterPlasmid Maxi Kit (QIAGEN, Duesseldorf, Germany), the DNA was 
quantified using NanoDrop ND-1000 (NanoDrop Technologies, Wilmingon, DE).
Fig.11 Transfection scheme
For each of the four SCLC cell line selected (H69, H526, DMS79 and GLC14), 
Phoenix packaging cells were seeded 2.8x105 cell/well in a six wells plate, the 
day after the cells were transfected with 5 μg plasmid DNA and 10 μl 
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) in 1 ml of DMEM for 5 
hours at 37°C. After the incubation 1 ml DMEM with 20% FBS was added and 
the day after the medium was changed. 1ml of medium contained retroviral 
vector particles, produced in the Phoenix packaging cell line, were filtered and 
introduced into SCLC cell lines with Polybrene 8 μg/ml (Millipore, Billerica, MA) 
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and 5 ml fresh medium. 5x105 cells of H69, H526, DMS79 and GLC14 were 
seeded 12 hours before the infection (Figure 11).
After transduction, the SCLC  cell lines were selected with 1 mg/ml G418 
(GIBCO-Invitrogen, Carlsbad, CA) for 14 days, then stable transfectants 
Luciferase expression in 105 live intact cells was examined using Luciferase 
Assay Reagent (Promega, Madison, WI) and measured with a spectral 
scanning multimodal plate reader (Varioskan Flash, Thermo Scientific, 
Whaltham, MA) in the 560-670 nm range of absorbance. Six different dilution 
(106, 105, 104, 103, 102, 10) of luciferase positive SCLC  live intact cells were 
analysed on the LB 981 (Berthold Technologies) after added of 100 μl of D-
Luciferin Steady- Glo® Luciferase Assay System (Promega, Madison, WI).
3.1.9 Establishment orthotopic xenograft models
All experiments involving animals were reviewed and approved by the 
Bioethical Committee of Bologna University, Italy and by  Italian Ministry of 
Health. Animals were kept under pathogen free conditions, with ad libitum 
access to food. Orthotopic xenograft models were established by injection of 
1.5x106 H69 and H526 in 20 μl NaCl solution. 6-week-old NOD/SCID mice 
(Charles River Laboratories, France) were anesthetized with 0.3 mg/kg body 
weight Zoletil 100 and Atropine Sulphate 1mg/ml, and injected in the pulmonary 
parenchyma through the ribs of the mice. No mice died as a result of this 
treatment. General physical status of the animals were recorded daily, and mice 
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were killed by cervical dislocation after being anesthetized with 0.3 mg/kg body 
weight Zoletil 100 (Virbac S.r.l., Carros Cedex, France), when showing signs of 
poor health. The cancer progression was monitored every 7 days for a total of 5 
weeks. The tumour presence was confirmed in each models with 
Bioluminescence Imaging analysis and histology. 
3.1.10 Molecular imaging
Mice anesthetized with 0.5 mg/kg body weight Zoletil 100 (Virbac S.r.l., Carros 
Cedex, France) in association with Atropine sulfate were i.p. injected with 150 
mg/kg Dluciferin (Synchem OHG, Felsberg, Germany) dissolved in PBS, and 
were imaged with the low-light imager system LB981 (Pharmaceutical 
Sciences, S.Orsola-Malpighi Hospital, University  of Bologna, Italy). To 
investigate the kinetics of the in vivo reactions, mice inoculated 14 days prior 
with H69-Luc cells were imaged for 20 min with sequential 1-min exposure. 
Mice were imaged for 20 min with sequential 1-min exposure during imaging 
sessions conducted immediately after i.p. injection of D-luciferin. The collected 
images were used to generate kinetics plot for luciferase, which were used to 
determine the optimal temporal windows for subsequent experiments.
Mice inoculated with H69-Luc cells were placed in supine positions inside the 
instrument and imaged for 3 min, beginning at 8 min after the luciferin injection. 
For each acquisition, the bioluminescent signal from the ROI was depicted as a 
pseudocolor image superimposed on a greyscale photographic image. The 
Winlight software version 2.9 of the low-light imager system LB981 (Berthold 
technologies, Wildbad, Germany) was used to analyze the BLI data. The 
luminescent signals were calculated as photon flux per second (ph/s) 
considering a ROI 2246 mm2.
3.1.11 Treatments and in vivo antitumor efficacy evaluation
To validate our mouse model we used the same antitumoral agents given in 
clinic. Our goal is to evaluate the tumor regression in mouse and to correlate 
this regression with the human pathology course.
52
From man to mouse model
It is not possible to estrapolate the animal dose only by scaling down from 
human dose (HED), It is necessary to apply a formula named body surface area 
(BSA) normalization method [Reagan-Shaw S. et al. 2008]:
Animal Dose (mg/kg) = Human Dose (mg/kg) * (Human km / Animal km)
To convert the usual clinic mg/m2  into the mg/kg, we can use the km values in 
table below [http//:dtp.nci.nih.gov]:
Tab. Representative Surface Area (BSA) to weight ratios (km) for various species
Alternatively, the table below gives approximated factors for converting doses 
expressed in terms of mg/kg from one species to an equivalent surface area 
dose expressed as mg/kg in other species tabulated.
                                                                     To
From
Mouse 20g Rat 150g Monkey 3kg Dog 8 kg Man 60 kg
Mouse 1 ½ ¼ 1/6 1/12
Rat 2 1 ½ ¼ 1/7
Monkey 4 2 1 3/5 1/3
Dog 6 4 2/3 1 ½
Man 12 7 3 2 1
To express a mg/m2 dose in any given species as the equivalent mg/kg dose, 
divide the dose by the appropriate km factor. 
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In vivo treatments
In clinic the standard protocol to treat SCLC is an association between Cisplatin 
(CDDP) and Etoposide (VP-16). The treatment schedule is the following: 
VP16 110 mg/m2 for three days and CDDP 60mg/m2 only the first day [Puglisi 
M. et al. 2010]. The translated regimens exceeded the MTD currently found in 
literature [Houghton PJ. et al. 2010] so we decided to set the regimens as:
Etoposide 12 mg/kg day 1, 2, 3(First week); 15 mg/kg day 1, 2, 3
Cisplatin 3.5 mg/kg day 1(First week); 4.5 mg/kg day 1
The treatments started after 15 days from the first positive signal and was 4 
weeks long. Etoposide and cisplatin were obtained from Hospital Drug 
Repository. The drugs were dissolved in physiological saline. As placebo control 
5 mice were treated only with physiological saline.[Nemati F. et al. 2000]
Tumor regression evaluation after treatment
Tumor regression was evaluated by BLI. Weekly mice received an 
intraperitoneal injection of 150 mg/kg D-luciferin from Gold Biotechnology (St. 
Louis,MO,USA) and placed in the light-tight chamber od a cooled CCD camera 
system LB981 (Berthold technologies, Wildbad, Germany) under Zoletil 
anaesthesia. Photographic and luminescent images were acquired 8 min after 
D-luciferin injection in supine position for 3 minutes. The Winlight software 
version 2.9 of the low-light imager system LB981 (Berthold technologies, 
Wildbad, Germany) was used to analyze the BLI data. The luminescent signals 
were calculated as photon flux per second (ph/s) considering a ROI of 2246 
mm2. 
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3.1.12 Statistical Analysis
Both in vitro and in vivo data were presented as means ±  Standard Error Mean 
(SEM). In vitro data were from at least three independent experiments.
For the Xenograft mouse models the bioluminescence intensity relative to the 
tumor progression was reported as mean ±  SEM (standard error of mean) 
considering the photon flux (ph/s) as the sum of prone signals for each mouse 
after background subtraction.
3.1.13 Histology and immunohistochemistry
Each small cell lung cancer sample was divided into two parts. A piece was 
frozen in liquid nitrogen and it was kept at -80°C for molecular analysis and an 
other piece was fixed in formalin for histological analysis.
Murine tissues were fixed in 4% formalin, dehydrated, embedded in paraffin, cut 
into 4 μm sections and stained with hematoxylin an eosin (H&E) methods. Bone 
marrow and peripheral blood were evaluated with May-Grunwald-Giemsa 
staining. For H&E staining, tissue sections were subjected to subsequent 
incubations in toluene, 100% ethanol, 95% ethanol, 70% ethanol, distilled water, 
hematoxylin, distilled water, eosin, distilled water, 70% ethanol, 95% ethanol, 
100% ethanol and toluene. After coverslip  application, slides were observed by 
light microscopy. . For May-Grunwald-Giemsa staining, the slides with blood 
smears were subjected to subsequent incubation with May-Grunwald for 3 min, 
washing in water, incubation with Giemsa for 7 min, washing in distilled water. 
After coverslip application samples were observed by light microscopy.
SCLC tissue sections were processed for immunohistochemistry. Sections were 
subjected to subsequent incubations in xilene, 100% ethanol, methanol and 
0,3% hydrogen peroxide, 96% ethanol, 70% ethanol, distilled water and then 
incubation in citrate buffer in pressure cooker. The sections were washed with 
1x PBS, incubated with goat serum for 15 min at room temperature, washed 
with 1x PBS and incubated with 1:50 anti-N-Myc primary antibody  (Oncogene) 
over night. The day after the slides were washed in 1x PBS and they  were 
incubated with anti-mouse secondary antibody (DAKO, Evision) for 20 min. 
After wash in 1xPBS, they were developed with a 5% Di-Amino-Benzidine 
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chromogen in TAI Buffer pH 7.6 with 3% hydrogen peroxide. After wash in 1x 
PBS slides were subjected to subsequent incubations in distilled water, 
hematoxylin, distilled water, 70% ethanol, 95% ethanol, 100% ethanol and 
toluene. After coverslip application, slides were observed by light microscopy.
3.2 Basal cell carcinoma
3.2.1 NEB1 cell culture
The PTCH knockdown models were generated by M.Rahaman, as a part of his 
PhD course, using NEB1 cells which originate from epidermal keratinocytes and 
are immortalised using HPV16 [Morley et al. 2003]. NEB1 cells were retrovirally 
transduced with PTCH1 shRNA constructs termed 29A and 189A that target 
exons 3 and 24 respectively. A non-targeting scramble control vector was used 
to create a control cell line.
Scramble control non-targeting sequence: GCGCGATATATAGAATACG 
29A target sequence exon 3: AAGGTGCTAATGTCCTGACCA 
189A target sequence exon 24: AAGGAAGGATGTAAAGTGGTA
NEB1 cells were cultured in keratinocyte growth medium (KGM) consisting of 
Alpha MEM and heat inactivated foetal bovine serum (Lonza, Slough, UK), L-
glutamine and penicillin/streptomycin (PAA Laboratories, Somerset, UK). The 
KGM supplement was made up of epidermal growth factor (EGF), 
hydrocortisone, insulin (bovine pancreas), adenine and cholera toxin (Sigma, 
Poole, UK). Cells were incubated at 37°c in 5% CO2. Cells were passaged at 
70% confluence, detached using Tripsin-EDTA
3.2.2 Pharmacological inhibitors
To investigate Hedgehog pathway and its connection with other pathways and 
their role in BCC aetiology, NEBs cell line were treated with several 
pharmacological inhibitors.
56
Inhibitor Target Company Details
AG1478 
(658552) EGFR Merck
Cell permeable, reversible, 
competitive inhibitor
Cyclopamine-KAAD   
(239804) SMO Merck Cell permeable, competitive inhibitor
SANT1
(559303) SMO Merck Cell permeable, competitive inhibitor
UO126
(662005)
MEK Merck Cell permeable, non-competitive 
inhibitor
3.2.3 RNA isolation and gene expression analysis
RNA isolation and gene expression analysis was performed as already reported 
in paragraph 3.1.2. The primer sequences designed to analyse selected gene 
overexpressions in BCC in vitro model were:
GENE FORWARD PRIMER REVERSE PRIMER T°
DUSP6 CCGCAGGAGCTATACGAGTC TTGAGCTTCTTGAGCAGCAG 60
EGFR TCAAATTGTGCCGAACAAGA ATCTGACATTGGGGTTCCAG 57
ELK GAAGCCATTCCTTTGTCTGC CCCTATTGAAAAGCCCCATT 60
FOS GGAATTAACCTGGTGCTGGA TCAGACCACCTCAACAATGC 60
GAPDH GTGAACCATGAGAAGTATGACA CATGAGTCCTTCCACGATACC 60
GLI1 GAAGACCTCTCCAGCTTGGA GGCTGACAGTATAGGCAGAG 60
GLI2 TGGCCGCTTCAGATGACAGATGTTG CGTTAGCCGAATGTCAGCCGTGAAG 58
JUN ACAGAGCATGACCCTGAACC CCACCATGCCTGCCCCGTTG 60
PTCH1 ACTCGCCAGAAGATTGGAGA TCCAATTTCCACTGCCTGTT 58
SMO GGCTGCTGAGTGAGAAG CTGGTTGAAGAAGTCGTAGAAG 58
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3.2.4 Western Blot
Western Blot was performed as already reported in paragraph 3.1.3 and 3.1.4. 
We used the following primary antibodies (diluted 1:1000):
Antibody Company Type Size(kDa)
EGFR Santa Cruz Goat polyclonal 170
ERK Cell Signalling Rabbit polyclonal 42, 44
GLI1 C18 Abcam Rabbit polyclonal 27
GLI1 H300 Santa Cruz Rabbit monoclonal 45
MEK Cell signalling Rabbit monoclonal 45
pEGFR Y845 Santa Cruz Rabbit polyclonal 170
pEGFR Y1173 Santa Cruz Goat polyclonal 170
pERK E10 Cell Signalling Mouse monoclonal 42, 44
pERK 20G11 Cell Signalling Rabbit monoclonal 42, 44
pMEK Cell Signalling Rabbit polyclonal 45
PTCH C20 Santa Cruz Goat polyclonal 140
SMO C17 Santa Cruz Goat polyclonal 85
3.2.5 Immunocytochemistry
Immunocytochemistry  staining was used to determine the cellular localisation of 
proteins. Cells were initially  seeded in 12 well plates on top  of 18mm diameter 
glass cover slips (VWR International Ltd, Leicestershire, UK). The cells were 
washed twice with PBS before being fixed with 4% paraformaldehyde for 15 
minutes. Cells were then washed with PBS three times and permeablised in 
triton X-100 (Sigma, Poole, UK) for 10 minutes. The cells were then blocked in 
3% BSA (Fisher Scientific, Leicestershire, UK) for 30 minutes followed by the 
addition of the primary antibody diluted 1:1000 in 3% BSA for 1 hour. Following 
three PBS washed for 5 minutes, a fluorescence dye labelled secondary 
antibody diluted to 1:800 in PBS was added and incubated for 1 hour while 
being protected by light. Alexa 488 and Alexa 568 secondary antibodies 
(Invitrogen, Paisley, UK) emit green and red fluorescence respectively. The cells 
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can also be stained for another antibody with an alternate secondary staining 
colour for co-localisation for example in which case, the primary and secondary 
antibody incubations were repeated. After three PBS washes, the nuclei of the 
cells were stained with 0.1μg/ml of DAPI for 5 minutes before a final wash in 
PBS. Coverslips were mounted onto microscope slides using Vectashield 
fluorescence mounting medium (Vector Laboratories Ltd, Peterborough, UK) 
and stored at 4°c away from light. The slides were viewed and images taken on 
the Zeiss LSM 510 Meta Confocal Microscope.
Images taken by the confocal microscope were quantified using Image J 
software [Collins 2007]. Images were edited to only show the fluorescence 
channel of the protein of interest and then converted to greyscale. Cells were 
selected and analysed based on the intensity of pixels taking into account the 
size of the cell. The relative density was then calculated which indicates the 
intensity of staining.
3.2.6 Matrigel based organotypic culture
The Matrigel organotypic culture provides a base for an artificial skin model. A 
dermis layer is created using Matrigel, collagen and fibroblasts. Keratinocytes 
are then seeded on top of the ‘dermis’ layer and cultured with an air liquid 
interface where the fibroblasts grow in culture media but not the keratinocytes. 
This to an extent mimics the skin in vitro.
One day  prior to the experiment, Matrigel (BD Pharmingen, NJ, USA) is taken 
from -20°C storage and allowed to defrost overnight at 4°c while on ice. On the 
day of the experiment, a mix is made up of 350 μl of Matrigel, 350 μl of Rat tail 
Collagen type 1 (Millipore, Watford, UK), 100 μl KGM media, 100 μl of FBS per 
gel. At this point, the mix is acidic therefore 1 M NaOH is added drop by drop 
until the solution changes from yellow to pink. 500,000 fibroblasts re- 
suspended in 100 μl are added to the mix and all components are gently  mixed 
in a 50 ml falcon tube avoiding any bubble formation. 1 ml of the mix is 
dispensed into the well of a 24 well plate and left in the incubator at 37°c, 5% (v/
v) CO2 for 2 hours. Once the gel has set, 1 ml of KGM media is added to the 
top of the gel and incubated overnight.
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The 1 ml of media was then removed from the gel and a 4.7 I.D x 8 mm cloning 
ring (Fisher Scientific, Leicestershire, UK) is pressed onto the gel within the 
well. This dislodges the gel from the walls of the well plate and provides an 
enclosed space to add 500,000 NEB1 cells resuspended in 500 μl of KGM 
media. This ensures that the NEB1 cells settle and grow on the surface of the 
gel. The gel is incubated overnight at 37°c, 5% (v/v) CO2.
Stainless steel wire gauze that is sculpted to provide a raised platform is placed 
within a 6 well plate. A single Cyclopore 0.4 μm polycarbonate membrane with a 
13 mm diameter (Whatman, Kent, UK) is placed on top of the gauze. The ring is 
removed from the gel and placed directly  on the membrane. 4.5 ml of KGM 
media is added to the well ensuring that there are no bubbles underneath the 
gauze and that the media does not drown the gel. This allows the dermis part of 
the gel to receive media from the bottom while the NEB1 cells on the top do not. 
The organotypic model is incubated for 28 days or more with weekly media 
changes. At the end of the experiment, gels were either snap  frozen of 
embedded in wax for histological sectioning.
3.2.7 Immunohistochemistry
To further investigate the activity of EGFR pathway in BCC, we performed 
immunohistological studies on human BCC and murine BCC. Mouse BCC 
tissues were kindly provided by Dr.Mancuso. In their laboratory in Rome, Dr 
Mancuso and colleagues created a Ptch+/- mouse model that after X-ray 
irradiation during the telogen phase develop BCC-like tumors. If irradiated 
during the anagen phase of the hair cycle they  develop  more aggressive-
infi l t ra t ive tumors. We used these t issues to per form c lass ic 
immunohistochemical analysis as already reported in paragraph, using 
antibodies already listed in tab.
 3.2.8 PTCH +/- mice colony
All the experiments involving animals were reviewed and approved by the 
Bioethical Committee of Bologna University, Italy and by  Italian Ministry of 
Health. Animals were kept under pathogen free conditions, with ad libitum 
access to food. Ptch +/- mice were generated by M.P Scott and E.H. Epstein 
(Stanford University) and purchased from Jackson Laboratory (Bar Harbor, ME)
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[88]. They were C57BL/6 and DBA/2J F1 hybrids, and were heterozygous for a 
deletion of exons 1 and 2 and insertion of the lacZ and neo genes. Genomic 
DNA was isolated from mouse-tail tips harvested when animals were 17 days 
old. The lysis buffer used is constituted of Tris 1 M pH8.5, EDTA 0.5 M pH8, 
NaCl 5 M, SDS 10% and water. Each tail tip  was incubated over-night in 
agitation in 500 μl lysis buffer and 2.25 μl proteinase K(Sigma). The suspension 
was put in 500 μl iso-propanol, gently  mixed and DNA tail was picked and put in 
100 μl Elution Buffer over-night at 37°C. Each DNA sample was quantified twice 
with the NanoDrop  ND-1000 spectrophotometer (NanoDrop  Technologies, 
Wilmingon, DE). The genotypes of Ptch +/- transgenic mice were determined by 
qualitative PCR analysis using primers: PTCH mutR CAC GGG TAG CCA ACG 
CTA TGT C; PTCH mutF GCC  CTG AAT GAA CTG CAG GAC G; PTCH wtR  CTG 
CGG CAA GTT TTT GGT TG; PTCH wtF AGG GCT TCT CGT TGG CTA CAA G. 
PCR reaction contained 300 ng gDNA, Buffer II 1x (Applied Biosystem, Roche), 
0.2 mM dNTPs, 2 mM MgCl2, 1 μM primer reverse and forward, 0.03 U/uL Taq 
DNA polymerase (Euroclone). We used PTC-225 Peltier Thermal Cycler (MJ 
Research) and PCR reaction conditions were 1.5 min at 94°C, for 35 cycles: 30 
sec at 94°C, 1 min at 69°C, 45 sec at 72°C; final step  of 2 min at 72°C. We 
analysed the PCR product on a 1% Agarose gel with GelRed in TBE 0.5x
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CHAPTER 4
RESULTS
4.1 MYCN characterization in SCLC cell lines
H69, H526 and H82 were already  been characterized in our lab, and to picture the 
complete panorama of this aggressive neoplasia, we analysed other ten cell lines, which 
carried different features.
I first evaluated the expression of Myc family  genes (MYC, MYCN and MYCL), SCLC 
markers.
As reported in Figure 12, H69, H526, N592 and GLC14 showed MYCN overexpression at 
the expense of lower expression of MYC and MYCL. All the other cell lines, as well, 
overexpress preferably only one of the three genes.
Fig.12 Myc family genes mRNA expression in different SCLC cell lines
NMYC overexpression was correlated with N-Myc protein in the same cell lines, after 
Western Blot analysis (Figure 13).
62
Fig. 13 Western Blot analysis of RH30, GLC14, GLC16, GLC19, H69, H526, N592 
The presence of MYCN amplification was also confirmed by FISH from all the four cell 
lines.
                   Fig.14 FISH of MYCN probe to nuclei of SCLC cell lines H69 (A) and H526 (B)
Fig.15 FISH of MYCN probe to nuclei of SCLC cell line N592
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Fig.16 FISH of MYCN probe to interphase (A) and metaphase (B) nuclei of SCLC cell line GLC14
H69 and H526 have been characterized previously in my lab, and they showed MYCN 
amplification (Figure 14A-B: Green probe represents MYCN gene). The amplification of 
MYCN gene was, then, verified by FISH in two other SCLC cell lines. In particular, GLC14 
derived from a patient before chemotherapy treatment. The N592 cell line shows the 
duplication of chromosome 2 and the presence of green signal concentrated in well-
defined areas suggests the presence of HSR(Homologous Staining Region) (Figure 15: 
"gene specific" probe = green signal; centromeric probe for chromosome 2 = red signal).
FISH analysis of GLC14 cell line shows the triplication and quadruplication of chromosome 
2 and an abundant amplification of MYCN gene. Moreover, Figure 16B suggests an 
episomal amplification of MYCN, already found in medulloblastoma [Surace C. et al. 
2008].
4.2 In vitro chemotherapeutic treatments
I defined dose-response curves for three compounds on cell lines that have proved to be 
NMYC  amplified: H69, N592 and GLC14. Chemotherapy is currently used in standard 
protocols and it is characterized by high toxicity due to the incomplete specificity of these 
drugs to cancer cells. The use of a molecule that does not show toxicity as the PNA in 
combination with these drugs could then work around this problem by allowing the same 
therapeutic effect at reduced doses.
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CDDP H69 N592 GLC14
R2 0,9886 1 0,9834
EC50[uM] 0,6119 0,009 30,52
CBDCA H69 N592 GLC14
R2 0,9472 0,9667 0,996
EC50[uM] 85,21 362 272,4
VP16 H69 N592 GLC14
R2 0,9962 0,9692 0,8765
EC50[uM] 6,859 52,67 71,51
A B
C
Fig.17 Dose-response curves for three chemotherapy drugs in SCLC cell lines with amplification of MYCN. 
CDDP = cisplatin, CBDCA = carboplatin; VP-16 = Etoposide EC50 = concentration of drug that defines the 
50% cell inhibition. A) CDDP; B) CBDCA and C) VP-16
4.3 In vitro anti-MYCN PNA treatment
Four cell lines, H69, GLC14, N592 and H82 were treated with 20, 15, 10 and 5 μM anti-
MYCN anti-gene PNAs-NLS (PNAwt), for 24 hours and the IC50 (concentration of drug 
that induces the increase of a cycle of ∆∆Ct or a 0.5 Fold change of MYCN tansgene 
transcript) was evaluated by semi-quantitative Real-Time PCR, normalizing the values on 
the β-actin housekeeping gene. The duration of treatment was derived from previously 
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made experiments. To test the specificity and the possible toxicity of the PNA an anti-gene 
anti-MYCN PNAmut was used, whose sequence has been altered by  three point 
mutations. 
Anti-gene PNAwt significantly inhibits the transcription of MYCN transgene 24 hours after 
treatment. Figure 18 shows an inhibition by 90% in H69 cell line, 65% in GLC14 and 55% 
in N592, using PNA at 15uM, with IC50 reported in Table 3. On the contrary, NMYC was 
not inhibited in H82 cell line, and to obtain an IC50 we used a Compusyn extrapolation 
method.
A
B C
D
Fig.18 Dose-response curves for A)H69; B)GLC14; C)N592 and D)H82
66
Cell line IC50
H69 5.86 uM
GLC14 6.96 uM
N592 13.34 uM
H82 272.8 uM
Tab.3 IC50 values
The anti-gene PNAmut showed, instead, no significant effects on cell lines characterics.
4.4 MYCN-amplified SCLC xenograft orthotopic mice models
4.4.1 In vitro validation of bioluminescent signal
In this part of my project I developed xenograft orthotopic SCLC murine models for a next 
pharmacological study. For these models we decided to use a new bioluminescence type 
of in vivo imaging monitoring system. The luminescent imaging system requires the 
introduction of a reporter gene, the luciferase enzyme gene, that allows real-time 
monitoring of cell growth in vivo. In Figure 19, RLU (Relative Luminescence group) signal 
graph of the chosen transfected cell lines. All of them stable express the luciferase gene 
with H69 cell line showing the highest luminescence.
Fig.19 Luciferase assay
Stably transfected H69 cells subsequently used for in vivo experiments were analyzed to 
identify the specific luciferase emission peak (attended on 560 nm) and to identify  a 
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correlation between luciferase expression and cells number. The luciferase emission 
spectrum analysis was obtained after the addition of D-luciferin at whole living cells.
The results showed that the cell line presented a relative luciferase emission peak (560 
nm) (Figure 20A) highlighting a perfect linear correlation between number of cells and 
photons detected (Figure 20B).
                 
Fig. 20A
               
Fig.20B
4.4.2 In vivo bioluminescent imaging
For in vivo study twenty mice were used: 10 were inoculated with 1,5x 106 H69-luc cells, 5 
with 1,5x106 H526-luc and 5 mice constituted the control group. Our previously 
experiments showed a higher incidence using 1.5x 106 compare with 3x106 cells (Figure 
21). 
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Fig.21 H69 tumor incidence
Mice were monitored weekly by examination of in vivo bioluminescence.
The temporal window for in vivo analysis was determined by the kinetics of biodistribution 
of D-luciferin, and it identified the time interval at which the signal is stable and the 
intensity of the signal is maximum. Figure 22 shows the acquisitions carried out for 1 min, 
15 sec intervals for 15 min in total.
Fig.22 In vivo kinetics of bio-distribution of D-luciferin. The acquisitions carried out for 1 minute, 15 second 
intervals for 15 minutes in total on the same mouse after the somministration of D-luciferin.
The data obtained with the luminometer showed a peak signal from the eighth minute that 
can be used up  to 12 minutes. The range of acquisitions between the 8 to 12 minutes after 
injection of D-luciferin was used for all orthotopic models to analyze the tumor burden and 
progression.
After this experiment, each animal was analyzed with NightOwl Berthold LB981 
luminometer to detect the presence of the tumor. Under anesthesia each animal was 
injected with D-Luciferin substrate to a concentration of 150 mg/kg. After 8 minutes it was 
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scanned for 3 minutes. The animals were monitored every seven days starting one week 
after inoculation with BLI. Figure 23 shows tumor progression in a mouse for each model, 
it is clear the evolution of the tumor marked by luminescence signal at different time of 
recording, covering a time period ranging from 4 weeks post-inoculation (first appearance 
of the signal ) at 10 weeks (endpoint). The xenograft orthotopic model obtained injecting 
H526luc showed a tumor characterized by a shorter latency (four weeks) and a higher BLI 
signal compared to xenograft orthotopic model obtained injecting H69luc.
H69lu
H526luc
Fig.23 In vivo monitoring of two different SCLC Xenograft Orthotopic mice models. The graph represents of 
tumor burden onset and progression at different timepoints (left side); signal detected from Berthold 
luminometer once a week starting one week after day of cells injection (right side).
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For one of the 10 mice injected with H69luc cell lines, we report the tumor progression by 
scan imaging. As shown in Figure 24, it was also possible to detect a bone metastasis and 
his growth during the weeks.
Fig.24 In vivo monitoring of tumor burden onset and progression at different timepoints
4.4.3 Mouse model validation
5 mice were inoculated with H69-luc cells and at the first bioluminescent signal they 
underwent a therapy with Cisplatin and Etoposide. 5 mice were taken as placebo control 
and received only saline solution.
We analyzed the data from mice become positive for BLI within the fourth and the sixth 
week. As already reported in Figure 23 they showed a 5 weeks latency and a following 
quantum growth. The chemotherapy group shows a decrease that starts at the seventh 
week, after two treatment cycles, and continues to decrease until it gets back to basal 
levels around the eleventh week.
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Placebo
Mouse N°10 
Fig.25 Tumor progression curve of both treated and untreated mice and the related bioluminescent images
This trend becomes even clearer translating the data in survival rate: the average life in 
the placebo group is 65 days compared to 85 days in the chemotherapy group.
Placebo
Chemotherapy
Fig.26 Different survival between Chemotherapy group (red line) and placebo group  (blue line). An average 
survival of 85 days compared with only 65 days for the placebo control.
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4.4.4 Ex vivo analysis of xenograft orthotopic tumor
The analysis was performed ex vivo on the mass removed at late stage of the disease. 
Figure 27 shows the altered lungs morphology (B) and confirms that photons detected by 
CCD camera were produced in these organs (C). The luminescence signal ex vivo is much 
sharper, skin, adipose tissue ribcage attenuate the intensity distribution and the photons 
detected. This analysis has allowed an assessment of the organ specific tumor mass, 
highlight that right lung, where the cells were implanted, is dramatically deformed.
Fig.27 Tumor mass ex-vivo analysis
Fig.28 
The autopsy allowed collection of tumor samples useful for the histological and molecular 
evaluation. From the post-mortem examination, all positive animals have a tumor mass 
located predominantly  in the chest region. At advanced stage, the tumor mass alters the 
structure of surrounding organs, for example it is possible find adhesion part. The tumor 
masses occur heterogeneous in the samples in which it is possible to distinguish necrotic 
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regions (Figure 28). It has been found the presence of metastases at bones level. The 
tumor presence was confirmed with histological analysis and the presence of human 
MYCN was seen with immunohistochemistry.
Histological data confirm that all samples were SCLCs. In Figure 29, we can see the 
characteristic structure of healthy lungs (A, B, C): bronchi (Br), bronchioles (Bi) and alveoli 
(Al). This structure is completely altered in the tumor mass (D, E, F): there are a lot of 
them (Mt) infiltering the lung, constituted of non-organized cells. Near the tumor, the alveoli 
look like crushed. Within the tumor mass we can also notice blood vessel sections.
Fig.29 H&E staining of normal tissue (A,B,C) and tumor tissue (D,E,F)
Immunohistochemistry (IHC) stainings evidence the high expression of MYCN oncogene 
in all samples. The majority  of cells in the samples resulted positive for the presence of N-
Myc to the detection with the chromogenic DAB that gives brown signal in cells nuclei. IHC 
was also performed on metastases tissue, confirming the abundance of N-Myc (Figure 
30).
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Figure 30 N-Myc IHC on murine SCLC tissue. Tumor and metastases (below)
4.5 In vitro and in vivo modelling of Basal cell carcinoma
4.5.1 Creation and characterisation of human keratinocyte cell line with stable 
PTCH1 suppression
The human immortalized cell line NEB1 was chosen for this study as they are widely used 
in skin research and retain the ability to differentiate [Morley et al., 2003]. In addition, the 
levels of PTCH1 and the downstream HH signalling component GLI1 were analyzed by 
qPCR to confirm that these cells were suitable for targeted PTCH1 suppression. Cell line 
was retrovirally transduced with a construct containing a non-targeting scrambled control 
(shCON) as well as two constructs targeting exons 3 (termed 29A) and 24 (termed 189A) 
of the PTCH1 gene respectively. After drug selection with Puromycin, clonal cell lines were 
derived by single cell seeding from the heterogeneous populations of NEB1-29A, and 
NEB1-189A. A number of clonal cell lines were derived from 29A and 189A heterogeneous 
populations based on their compact, BCC-like morphology and the level of PTCH1 
suppression was assessed by qPCR (Figure 31A). NEB1-189A-β1 cells showed the 
strongest suppression of PTCH1 which correlated with an increase of GLI1 and therefore, 
most of the studies were conducted on this particular clonal cell line. NEB1-189A-β1 will 
now be referred to as NEB1-shPTCH1.
Morphologically, NEB1-shPTCH1 cells displayed a more compact cobblestone-like colony 
formation compared to NEB1-shCON cells and parental NEB1 cells (Figure 31B).
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BFig.31: A)qPCR for PTCH1 and GLI1 in shPTCH1 clonal cell lines PTCH1 and GLI1 mRNA expression 
levels in NEB1-shPTCH1; B)PTCH1 suppression induces a highly compact morphology in human 
keratinocytes.
To confirm that the increase of GLI1 is specifically due to reduced PTCH1 activity in NEB1- 
shPTCH1 cells, a rescue experiment was performed by ectopically  expressing the 
PTCH1B isoform and analysing GLI1 expression. As the PTCH1B vector only contains the 
coding sequence (i.e. START to STOP codons) its mRNA is not subject to degradation by 
the PTCH1 shRNA as the hairpin targets a region that is downstream of the STOP codon 
in exon 24. Ectopic PTCH1B suppressed GLI1 to basal levels thus confirming that the 
increase of the latter is due to reduced PTCH1 function in NEB1-shPTCH1 cells.
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4.5.2 Characterisation of Hedgehog signalling components in NEB1-shPTCH1 cells
Having established that PTCH1 is strongly suppressed in NEB1-shPTCH1 cells, further 
characterisation at the protein level by immunocytochemistry confirmed a reduction of 
PTCH1 protein which was quantified by Image J software (Figure 32). The commercial 
(Santa Cruz) PTCH1-C20 antibody is specific to the C-terminus of the protein and this 
gave a distinct signal in the nucleus of NEB1-shCON cells which was reduced in NEB1-
shPTCH1 cells thus helping confirm antibody specificity. PTCH1 is generally  considered to 
be a transmembrane protein however, a recent study showed that the protein is cleaved 
and that the C-terminus resides in the nucleus where it can regulate GLI1 (Kagawa et al., 
2011).
A
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Fig.32: Immunofluorescent analysis of PTCH1 protein expression [A] NEB1-shCON and NEB1-
shPTCH1 cells stained for C-terminal PTCH1-C20. [B] Image J quantification for PTCH1 staining. 
Error bars represent mean ± standard deviation, student’s t-test shows a significant difference with 
95% confidence (p<0.05).
Consistent with the results of qPCR analysis (Figure 31 A), GLI1 protein was also found to 
be increased in NEB1-shPTCH1 cells. Two different antibodies were used with GLI1-C18 
detecting cytoplasmic and nuclear protein and GLI1-H300 detecting mainly nuclear protein 
(Figure 33). The reason for this is unclear but other studies in the laboratory  have shown 
that both antibodies detect ectopic GLI1 by Western blot analysis of keratinocyte protein 
lysates.
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Figure 33: Immunofluorescent analysis of GLI1 protein expression [A] NEB1-shPTCH1 cells stained for 
cytoplasmic GLI1-C18 and nuclear GLI1-H300. [B] Image J quantification for GLI1 staining. Error bars 
represent mean ± standard  deviation,  student’s  t-test shows a significant difference with 95% confidence 
(P<0.05).
Other components of the HH signalling pathway were also investigated in NEB1-shPTCH1 
cells. SHH was found to be decreased at the protein and mRNA level. SMO mRNA was 
also increased two fold in NEB1-shPTCH1 cells (Figure 34).
Fig.34: Analysis of HH signalling components in NEB1-shPTCH1 cells. qPCR for SMO. Error bars 
represent mean ± standard deviation.
4.5.3 Non-canonical GLI1 signalling in NEB1-shPTCH1 cells
To determine if the increase of GLI1 expression in NEB1-shPTCH1 cells is mediated 
through SMO (i.e. canonical HH signalling), NEB1-shPTCH1 cells were exposed to the 
SMO antagonist Cyclopamine-KAAD. As shown by qPCR and IF, over a period of 24 hours 
GLI1 expression was strongly suppressed in NEB1-shCON cells whereas it was not 
significantly altered in NEB1-shPTCH1 cells (Figure 35).
79
  Chapter 3 
111 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: GLI1 expression is not influenced by SMO pharmacological inhibition in NEB1-shPTCH1 cells 
[A] Immunofluorescent staining for GLI1-C18 and GLI1-H300 in NEB1 cells treated with 100 nM 
Cyclopamine-KAAD for up to 24 hours and [B] qPCR for GLI1. Error bars represent mean ± standard 
deviation. 
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Figure 35: GLI  expression is not influenced by S  r acological inhibitio  in NEB1-shPTCH1 cells; 
qPCR for GLI1 in NEB1 cells treated with 100 nM Cyclopamine-KAAD for up  to 24 hours. Error bars 
represent mean ± standard deviation.
In summary, shPTCH1 cell lines that were treated with the SMO inhibitors retained a 
higher GLI1 expression level (compared to shCON cells) which suggests that PTCH1 
regulates GLI1 via a SMO-independent mechanism. NEB1 cells exposed to SMO 
inhibitors was analysed for GLI2 mRNA levels which were lower in NEB1-shPTCH1 cells 
compared to NEB1-shCON. GLI2 mRNA expression in both cell lines were suppressed by 
Cyclopamine-KAAD which suggests that GLI2 signalling occurs via canonical HH 
signalling. Taken together, these data suggest that there is a canonical SMO-GLI1/GLI2 
signalling axis in shCON cells and a canonical SMO-GLI2 signalling axis in shPTCH1 
cells, but they  also indicate the presence of a non-canonical PTCH1-GLI1 signalling axis 
that is independent of SMO activity in shPTCH1 cells (Figure 36).
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Figure 3.17: Schematic diagram depicting a novel non-canonical PTCH1-GLI signalling pathway in 
shPTCH1 cells (right panel) 
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Fig.36: Schematic diagram depicting a novel non-canonical PTCH1-GLI signalling pathway in shPTCH1 
cells (right panel)
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4.5.4 Functional studies of NEB1-shPTCH1 cells
As well as investigating the HH signalling pathway, the in vitro BCC model was established 
to investigate specifically the effects of PTCH1 suppression upon certain aspects of 
keratinocyte biology including proliferation, invasion and anchorage-independent growth.
With regards, to proliferation rate, there was a slight but consistent decrease in NEB1-
shPTCH1 cells (29A and 189A) compared to the control. In contrast, NEB1-shPTCH1 cells 
were hyperproliferative when seeded onto a Matrigel based organotypic culture system 
although there was no evidence of invasion into the artificial dermis characteristic of 
superficial BCC or compact colony formation characteristic of nodular BCC (Figure 37).
Fig.37: Organotypic skin model of NEB1 cells
4.5.5 EGFR signalling in NEB1-shPTCH1 cells
Microarray analysis of NEB1-shPTCH1 cells revealed that a number of major signalling 
pathways are affected by the suppression of PTCH1. One significant pathway that was 
highlighted was the MEK/ERK pathway downstream of EGFR signalling. It has been 
shown that EGFR signalling modulates the expression of GLI1 in N/Tert keratinocytes and 
that a number of genes could be induced synergistically by GLI1 and EGF treatment. 
Furthermore, the GLI1 target genes were modulated by  EGFR signalling via MEK/ERK 
pathways (Kasper et al., 2006). Other studies have demonstrated that GLI1 and GLI2 
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expression is induced by EGFR mediated MEK/ERK signalling and that mouse BCCs 
treated with EGFR and GLI inhibitors reduced tumour growth (Schnidar et al., 2009).
In contrast, the Neill group  has previously  shown that the over expression of GLI1 in N/Tert 
cells reduces EGFR expression and that ERK activity is also repressed. Furthermore, 
pERK protein was not expressed in 13/14 BCC tumours whereas it was expressed in the 
epidermis indicating that the loss of pERK may be important for tumour formation (Neill 
GW. et al. 2008). These contradictions in the literature warrant further investigation to 
determine if MEK/ERK signalling is a viable therapeutic target for BCC treatment. As such, 
NEB1-shPTCH1 cells were analysed for the expression of EGFR signalling and 
downstream MEK/ERK components.
EGFR expression was shown to be reduced at the mRNA level and also by  western 
blotting (Figure 38 A and B). Downstream of EGFR, pMEK and pERK protein levels were 
also reduced in NEB1-shPTCH1 cells compared to NEB1-shCON cells (Figure 38 C). To 
confirm if MEK/ERK signalling expression was reduced in NEB1-shPTCH1 cells, the 
expression of several target genes known to be activated by MEK/ERK signalling including 
FOS, JUN and MYC were investigated by qPCR in NEB1 cells (Figure 37). The expression 
of all these genes was increased in NEB1-shPTCH1 cells (189A) and this was additionally 
confirmed in NEB1-29A cells.
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Fig.38: EGFR pathway expression in NEB1 cells: EGFR analysis by [A] qPCR; [B] western blotting; [C] 
Western blot for EGFR downstream targets pERK (E10), pMEK, MEK with ERK loading control.
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Fig.39: qPCR for ERK target genes in NEB1 cells [A] FOS, JUN, MYC, [B] DUSP6, ELK, SRF, [C] EGR1 and 
CXCL11 mRNA expression in NEB1 cells.
At the mRNA level, there is evidence that the ERK signalling pathway is active however 
western blotting revealed that protein levels of MEK, pMEK and pERK were decreased in 
NEB1-shPTCH1 cells compared to NEB1-shCON cells. This correlates with the finding 
that EGFR protein expression was reduced in NEB1-shPTCH1 cells however it does not 
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explain why ERK target genes would be increased. Intriguingly, immunocytochemical 
analysis of pEGFR revealed an increase of nuclear localization in NEB1-shPTCH1 cells 
(Figure 40 A). The reason for this is unclear but it could account for reduced MEK/ERK 
signalling due to weaker signals emanating from the outer cell membrane. Nuclear EGFR 
translocation is induced in cultured cells exposed to DNA damaging agents (including UVB 
irradiation) where it is linked with DNA repair and suppression of the apoptotic response 
(Xu et al., 2009).
Further analysis by immunocytochemistry revealed that pERK was more localised in the 
nucleus in NEB1-shPTCH1 cells which could account for the increase of the pERK target 
genes (Figure 40B). Also, immunocytochemical analysis of pMEK localisation was 
inconclusive although there was some evidence of nuclear pMEK in NEB1-shPTCH1 cells 
that was not observed in NEB1-shCON cells (Figure 40C).
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Fig.40: pEGFR, pERK and pMEK protein expression in NEB1 cells. Immunofluorescence staining of [A] 
pEGFR (Y1173 and Y845), [B] pERK (20G11) and [C] pMEK in NEB1- shCON and NEB1-shPTCH1 cells.
4.5.6 EGFR signalling and control of GLI expression in shPTCH1 cells
Several studies have shown that GLI1 transcriptional activity is increased by MEK/ERK 
signalling and it has also been shown that GLI1 expression is actually  induced by  MEK/
ERK signalling (Schnidar et al., 2009). To determine if MEK/ERK signalling regulates the 
increase of GLI1 in NEB1-shPTCH1 cells, cultures were exposed to the MEK inhibitor 
U0126 as well as the EGFR inhibitor AG1478. The expression of GLI1 returned to basal 
levels in the presence of both U0126 and AG1478 indicating that the increase of GLI1 is 
mediated by EGFR/MEK/ERK signalling (Figure 41). Intriguingly, inhibition of EGFR, led to 
an increase of GLI2 mRNA levels which raises concerns about the use of anti-EGFR 
compounds for the treatment of BCC and possibly other tumours.
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Fig.41: NEB1 cells treated with EGFR and MEK inhibitors
4.7 EGFR signalling pathway in human and murine BCCs
Despite demonstrating that the ERK pathway is more active in NEB1 due to the 
suppression of PTCH1, this does not correlate in BCC tissue. Immunohistological studies 
of pERK and pAKT in BCC tissue show that neither protein is active in BCC (Neill et al., 
2008; Hafner et al., 2012). My group  in London has done extensive analysis of EGFR 
signalling in BCCs and confirmed that pERK is not expressed in non-aggressive human 
BCCs (Figure 42). Interestingly, our group  has also shown that human BCCs express 
pMEK so why it does not phosphorylate its principal target ERK (the un-phosphorylated 
protein is expressed in the tumours) is surprising and under further investigation. 
Moreover, we have also shown that pERK is not expressed in mouse BCCs whereas 
pMEK is abundant (unpublished data) (Figure 43).
The expression of pEGFR, pERK and pMEK was examined in 15 non-invasive and 14 
invasive human BCCs (Figure 44). All phospho-proteins were expressed in normal and 
tumour associated epidermis (nuclear/cytoplasmic) but whereas pEGFR and pMEK were 
also present in all tumours (albeit at varying levels and with no apparent correlation), 
pERK was consistently absent in non-invasive BCCs; pERK staining was slightly higher in 
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invasive tumour islands but the main feature of these samples was that pERK was often 
localized to the stroma. pERK (but not pMEK) was dramatically  absent compared to the 
epidermis. Conversely, pERK (but not pMEK) was expressed in the stromal cells of a more 
aggressive BCC-like variant which correlates with the presence of stromal pERK in 
invasive human BCC.
pEGFR pMEK pERK
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Fig.42 pEGFR, pMEK and pERK expression in non-infiltrative BCC
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Fig.43 pMEK and pERK expression in murine BCC-like tumors
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Figure 44: pEGFR, pERK and pMEK immunohistochemistry scoring in BCC tissue: [A] pEGFR, pERK and 
pMEK scoring in non-invasive BCCs. [B] pEGFR, pERK and pMEK scoring in invasive BCCs 
Scoring: 0 = 0%, 1 = 1-29%, 2 = 30-59%, 3 = 60-100% * denotes presence stromal pERK staining
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CHAPTER 5
DISCUSSION
Prediction of human tumor response from preclinical data could reduce failure 
rates of clinical development of new anticancer drugs. The crucial question is 
therefore to define whether estabilished prclinical models, in vitro and in vivo, 
retain the characteristics of the human tumors from which they are derived. 
I focused my PhD course on development of preclinical models of two of the 
most common and aggressive malignancies: Small cell lung cancer (SCLC) and 
Basal cell carcinoma (BCC).
SCLC accounts for approximately 15% of bronchogenic carcinoma. SCLC is 
more responsive to chemotherapy and radiation therapy  than other cell types of 
lung cancer; however, a cure is difficult to achieve because SCLC very 
frequently  relapses and has a greater tendency to be widely disseminated by 
the time of diagnosis.
BCC, a slow-growing form of skin cancer, is the most common form of cancer in 
the Western World. Although BCC is a malignant neoplasm, it rarely 
metastasizes. The incidence of metastatic BCC is estimated to be less than 
0.1%. Nevertheless, after treatment, which is curative in more than 95% of 
cases, BCC may develop in new sites.
Although quite different, these two pathologies share important features:
- Lack of effective and decisive treatments;
- Need for new experimental models to test novel therapies.
The poor therapeutic efficacy achieved to date is a direct consequence of the 
lack of knowledge of molecular mechanisms underlying these diseases.
In our previous studies at the Laboratory  of Pediatric Oncology of the University 
of Bologna, we characterized the anti-tumor activity of a specific anti-MYCN 
PNA inhibitor able to silence human MYCN gene expression (Tonelli R. et al, 
2005) in MYCN-amplified NB cells: a potent and specific anti-tumor activity as 
well as an apoptosis induction were demonstrated. Following MYCN silencing 
also MDM2 protein level was reduced, rescuing p53 levels and inducing 
apoptosis in MA-NB cells (Slack A. et al, 2005). In a preliminary study, anti-
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MYCN PNA did not show toxicity  in no-expressing MYCN cells (Tonelli R. et al, 
2005).
MYCN amplification and overexpression have been found in both SCLC and 
BCC. In particular three of the members of the MYC family, c-MYC, MYCN and 
LMYC, have been shown to be amplified in tumors and tumor cell lines from 
patients with SCLC [Gazzeri et al. 1991]. MYC amplification is associated with a 
variant form of SCLC that has a more rapid growth rate than the classic type 
[Johnson BE et al. 1986]. 
The first part of the project has been dedicated to set up  appropriate preclinical 
in vitro and in vivo model to evaluate the potential therapeutic role of targeting 
MYCN in SCLC.
Thirteen SCLC cell lines have been characterized at the molecular level, by 
qPCR, WB and FISH to evaluate respectively mRNAs, proteins and DNA 
amplifications of c-MYC, MYCN and LMYC. Surprisingly in each cell line, only 
one member of the MYC  family genes has been found to be predominant. WB 
confirmed the expression of N-Myc protein in H69, N592 and GLC14 cell lines, 
and FISH confirmed the DNA amplification.
The same cell lines have been employed to test the antitumor activity of three 
chemotherapy compounds largely administered in clinical protocols: Cisplatin, 
Carboplatin and Etoposide.  
Cisplatin showed the highest efficacy  in all the cell lines tested, probably  due to 
its covalent binding to DNA and the consequent formation of cruciate ligaments 
between complementary strands, regardless of the cell cycle stage. Therefore 
the cytotoxic action indiscriminately  affects all cells. Moreover Etoposide results 
to be very effective on cells, although EC50 values are higher than Cisplatin. 
Etoposide is a cycle-specific compound and, by inhibiting the topoisomerase II 
enzyme, blocks the cells exclusively during their proliferative phase; this 
particular mechanism, more selective for cancer cells (rapidly proliferating 
compared to healthy cells) allows the drug to have a lower toxicity  and limited 
adverse effects compared to Cisplatin.
Among the antineoplastic drugs tested, Carboplatin is the least effective: higher 
concentrations are required to achieve the same effect obtained with Cisplatin 
or Etoposide. These results confirm literature data, in which elderly patients with 
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renal impairment capacity  tolerate better oral administration of Carboplatin 
[Puglisi M. et al 2010], due to the favorable toxicity profile of this drug.
In vitro studies performed on SCLC cell lines using anti-MYCN PNAwt showed 
cell growth inhibition activity only in the H69, N592 and GLC14 cell line, carrying 
MYCN amplification, while no inhibition was observed in H82 cell line. This 
result correlates with Real Time PCR assays, showing a significant change of 
expression in response to PNA treatment only in MYCN amplified cell lines. To 
evaluate the specificity of the molecule, we conducted a test with a mutated 
PNA that has confirmed that the effect is sequence specific. Therefore the data 
obtained, besides highlighting the critical role of MYCN amplification in this 
disease, can also be considered valid basis for a preclinical study.
All cell lines have been engineered to insert a stable expression of the 
luciferase gene; the transfection is rather complicated and each step presents 
several variables that could result in errors; for this reason the percentage of 
success of the method is not very high, and among all, only H69, H526, GLC14 
and DMS-79 cell lines passed positively the antibiotic selection phase.
Following completion of in vitro experiments, in vivo studies have been started.
As it’s well known, transgenic murine models better summarize the clinical 
development of pathologies. Currently  only a mouse model of small cell lung 
carcinoma have been developed [Berns A. et al. 2005]. The lack of models is 
due to a poor knowledge of the molecular mechanisms leading to 
carcinogenesis in this pathology and the role of pulmonary neuroendocrine cells 
from which SCLC originates.
Therefore, we created two orthotopic xenograft mouse models using H69-Luc 
and H526-Luc cell lines and in vivo bioluminescence imaging as a strategy.
Bioluminescence in vivo represents a method with no aspecific signal, widely 
used in preclinical oncology. It allows to monitor the presence of tumoral cells in 
internal organs, quantify tumor growth in real-time without animal sacrifice and 
identify metastases.
By intrapulmonary inoculation we created two models injecting H69 and H526 
luminescent cells respectively: tumor progression over time was monitored in 
both models.
We established excellent preclinical models; small cell lung cancer cells are 
able in vivo to organize and develop, generating a tumor mass recognized by 
histological analysis as Small Cell Lung Carcinoma. The described models 
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allow to monitor early development and tumor mass growth, which is very 
important since the only visible symptoms occur late. Not of secondary 
importance, the model created, compared to transgenic models and others 
based on PET analysis, can be developed in a relatively  short time, requires a 
low level of specialization and utilizes inexpensive reagents and equipment. 
By definition, an animal model for preclinical studies must be able to mimic 
accurately  the pathology, to assume with confidence that any  positive result 
obtained in animals is also translatable to men.
Since one of the main features of Small cell lung cancer is the immediate 
response to chemotherapy, one of the two mouse models has been validated 
using standard chemotherapy (Cisplatin plus Etoposide). 
As in clinical treatments, this model shows a decrease of BLI signal after two 
weeks of chemotherapy cycles. In addition, chemotherapy is well tolerated and 
does not affect drastically  the vital functions. The results are quite encouraging 
both in terms of efficacy and safety. Finally, the treated animals have an 
extension of survival of 20 days compared to the control and the placebo 
groups.
All these features make our preclinical models of Small cell lung carcinoma 
ideal for drug screening and for a better evaluation of potential new therapeutic 
agents against this disease. In the future it is expected to complete the 
development of these models by increasing the number of mice studied to 
improve the statistics and to define more precisely  the chemotherapy protocols 
to improve the toxicological profile.
In addition, other mouse models will be created using stabilized xenograft cells 
derived from patients relapsed or refractory to treatment, and the different 
models will be compared to one another.
Considering that the cell lines used (H69 and H526) were characterized in 
details and showed a pattern of substantial genetic alterations, the models 
developed may be used to evaluate the efficacy of target-specific molecules 
with the ultimate goal of being able to use in humans for personalized 
treatments based on the altered genes in each individual patient.
In the second part of the project, pre-existing preclinical in vitro and in vivo 
models of BCCs were used to find new targets for customized therapies. 
Moreover this was a chance to study the Hedgehog signalling pathway, one of 
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the most investigated pathway for its implications in the pathogenesis of certain 
types of cancer.
In vitro BCC model was developed by the suppression of PTCH1 in human 
keratinocytes using shRNA and the HH signalling pathway was characterized.
The validity of suppressing PTCH1 to create an in vitro model of BCC was first 
supported by  the observation that in two-dimensional culture some clonal 
NEB1-shPTCH1 cell lines cultured as more compact colonies compared to 
parental or control cells, thus showing a morphology similar to nodular BCC.
It is difficult to determine which form of BCC NEB1-shPTCH1 cells are 
modeling: in two-dimensional culture the morphology of the cells would suggest 
a nodular BCC while in organotypic culture they more likely resemble superficial 
BCC.
Matrigel based organotypic culture of NEB1-shPTCH1 cells did not result in 
BCC formation, as there might be the need of a certain level of PTCH1 
suppression to initiate tumour formation, whereas shRNA does not fully 
suppress PTCH1. However, there was evidence of a hyperproliferation of the 
epidermal layer and since NEB1-shPTCH1 cells present a high grade of PTCH1 
suppression, a separate event might be needed to occur before BCCs could 
develop. This could be obtained through UV irradiation as seen in mice studies 
or via other pathways that are linked to HH signalling. 
Most clonal cell lines also displayed increased levels of GLI1. The induction of 
GLI1 via PTCH1 suppression was confirmed by the fact that the increase of 
endogenous GLI1 was suppressed upon ectopic expression of the PTCH1B 
isoform which is not targeted by the PTCH1 shRNA construct. 
We also noticed that SMO and GLI1 expression is not suppressed upon 
exposure to SMO pharmacological inhibitors in NEB1-shPTCH1 and it is worth 
noting that no studies have convincingly shown that GLI1 expression is actually 
reduced in BCCs using clinical compounds such as GDC-0449 (Erivedge®). 
Various SMO inhibitors have been described including GDC-0449 however, 
many patients do not respond to these treatments and the levels of GLI1 have 
not been reported in non-responding tumours (Van Hoff et al., 2009). Indeed, 
having demonstrated that GLI1 is not suppressed by Cyclopamine-KAAD or 
SANT1 in shPTCH1 cells, the effects of anti-SMO inhibitors upon GLI1 
expression in BCCs requires further evaluation.
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This mode of non-canonical GLI1 signalling may occur through other pathways. 
The idea that HH signalling can occur non-canonically has been explored and is 
not entirely  a new concept. GLI1 was over expressed in NIH-3T3 cells and the 
increase of its activity was confirmed with a GLI1 reporter construct. Cells 
treated with Cyclopamine did not repress GLI1 reporter activity which only 
returned to basal levels when the cells were transfected with PTCH (3:1 ratio of 
PTCH:GLI1) (Rahnama et al., 2006). This shows that GLI1 is controlled by 
PTCH but signals independently of SMO. Also, if the HH pathway was linear 
(i.e. PTCH1 signals through to GLI1 without the influence of any other pathway), 
a lower amount of PTCH would need to be transfected into NIH-3T3 cells to 
suppress GLI1. Since three times the amount of PTCH to GLI1 is required, GLI1 
may be expressed thorough other non-conventional modes.
Analysis of the SMO protein sequence reveals a bipartite N-terminal nuclear 
localization sequence (NLS) which provides evidence that SMO has the 
capacity to localize to the nucleus. As NEB1 cells display nuclear expression of 
PTCH1, SMO and GLI1, then potentially this could explain why, despite the 
presence of a SMO inhibitor, GLI1 is activated.
The effectiveness of new SMO inhibitors to treat BCCs might depend upon the 
method by which the tumour was initiated (e.g. through PTCH1 mutations, SMO 
activation or UV associated DNA damage). 
Thus, one more time, it is extremely important to select the right animal model. 
In this study  we employed Ptch+/- mice that upon X-ray irradiation lost the wt 
allele and started to develop  BCCs. As already mentioned, if the mice have 
been irradiated during the telogen phase BCCs will be superficial; in contrast 
they will be more aggressive/infiltrative if the X-ray irradiation is administered 
during the anagen phase.
On this model we performed extensively IHC analysis to address the possibility 
for HH and EGFR to cooperate in BCC tumorigenesis. 
The EGFR signalling pathway and its downstream targets are altered in NEB1-
shPTCH1 cells due to the suppression of PTCH1. Neill and colleagues have 
previously shown that EGFR signalling influences GLI1 target genes in human 
keratinocytes and they demonstrated how a strong GLI1 activity  negatively 
regulates EGFR/ERK signalling (Neill et al., 2008). 
In the previous study a higher GLI1 overexpression in N/Tert keratinocytes was 
obtained through an EGFP-GLI1 fusion protein whereas NEB1-shPTCH1 cells, 
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with a modest increase of GLI1 levels, were used in the present study. However 
there was a reduction in EGFR mRNA expression in NEB1-shPTCH1 cells 
compared to NEB1-shCON cells. Interestingly, analysis of pEGFR (Y1173 and 
Y845) showed increased nuclear expression in NEB1-shPTCH1 cells compared 
to NEB1-shCON cells. Phosphorylation of Y845 has been implicated in 
maintaining activation of EGFR (Hubbard et al., 1994) while Y1173 
phosphorylation has been linked to ERK activation (Hsu et al., 2011). Despite a 
decrease in EGFR protein and mRNA expression in NEB1-shPTCH1 cells, 
downstream ERK and its target genes are more active.
Western blot analysis of EGFR downstream targets pERK and pMEK showed 
that there was reduced expression in NEB1-shPTCH1 cells compared to NEB1-
shCON cells. Similar to pEGFR expression, there was increased nuclear 
staining for pERK and pMEK in NEB1- shPTCH1 cells compared to NEB1-
shCON cells. Again, this suggests that pERK and pMEK are more active in 
NEB1-shPTCH1 due to nuclear protein localization. However, without a MEK/
ERK reporter construct, it would be difficult to determine if ERK is more active in 
the cells. NEB1 cells were difficult to lyse when attempting to perform a 
Luciferase assay therefore ERK target genes were analyzed.
Based on the data obtained from the microarray that suggests EGFR signalling 
is differentially regulated, ERK target genes were analyzed by qPCR in NEB1 
cells. Downstream targets of ERK were increased in NEB1-shPTCH1 cells 
compared to NEB1-shCON cells. As ERK is phosphorylated and translocates to 
the nucleus, it acts upon FOS, JUN, MYC and ELK transcription factors 
(Kerkhoff and Rapp, 1998). FOS and SRF are known to bind to each other to 
regulate DNA binding activity (Prywes et al., 1988). Also, active ERK has been 
shown to induce phosphorylation of ELK (Cruzalequi et al., 1999). EGR1 
expression in PC3 prostate cell lines has been shown to be mediated through 
the EGF induced ERK signalling pathway (Gregg and Fraizer, 2011). This along 
with the nuclear expression of pEGFR that may lead to increased expression of 
pERK and pMEK supports the idea that ERK signalling is more active in NEB1-
shPTCH1 cells compared to NEB1-shCON cells.
As mentioned earlier, the EGFR and HH signalling pathways are likely to be 
linked and that the over expression of GLI1 leads to differential expression of 
EGFR components in keratinocyte cell lines. The tight colony  formation 
observed in NEB1-shPTCH1 cells was also observed when GLI1 was over 
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expressed in N/Tert keratinocyes (Neill et al., 2008). In contrast, studies have 
shown that the EGFR and HH pathways are synergistically linked as 
demonstrated in N/Tert keratinocytes where 19 genes were found to be induced 
synergistically  by GLI1 and EGF treatment also; GLI1 target genes were shown 
to be modulated by EGFR signalling through MEK/ERK pathways (Kasper et 
al., 2006). This is further supported by the study of mouse BCC cell lines 
ASZ001 and BSZ2 (Ptch−/−) as well as CSZ1 (p53−/−). These cell lines express 
higher levels of EGFR mRNA compared to keratinocytes. By inhibiting both 
EGFR with gefitinib and GLI signalling with GANT61 there is a reduction of BCC 
growth which suggests that both are a good target for BCC therapy (Schnidar et 
al., 2009). Conversely, this suggests that the dysregulation of both pathways 
may lead to BCC formation or development.
The study also demonstrated that EGFR/MEK/ERK pathways increase GLI1 
and GLI2 expression (Schnidar et al., 2009) In agreement with this, the 
expression of GLI1 was reduced in NEB1-shCON and NEB1-shPTCH1 cells 
that were treated with the EGFR inhibitor AG1478 and both GLI1 and GLI2 were 
suppressed with the MEK inhibitor U0126. However, inhibition of EGFR, led to 
an increase of GLI2 mRNA levels which suggests that EGFR and HH signalling 
do not act in synergy with regards to control of GLI2 in human keratinocytes.
These data also shows that the inhibition of MEK/ERK effectively suppresses 
both GLI1 (canonical as well as non-canonical GLI1 that is not suppressed by 
SMO inhibitors) and GLI2 in NEB1-shPTCH1 cells which could be a good 
therapeutic target. In NIH-3T3 cell, MEK and ERK were able to stimulate GLI 
reporter activity and when MEK/ERK combined with either GLI1 or GLI2, there 
was a much greater induction of GLI reporter activity (Riobo et al., 2006 B). 
Based on this and the data generated that show activation of ERK signalling, 
GLI1 induction in NEB1-shPTCH1 cells may be mediated through ERK rather 
than the canonical HH pathway. The question then arises as to whether the loss 
of PTCH1 leads to MEK/ERK mediated GLI expression in a signalling mode that 
may not require SMO. This would explain why NEB1-shPTCH1 cells do not 
respond to SMO inhibitors to a certain extent but not why SMO siRNA 
represses GLI1.
Treatment of NEB1 cells with EGFR inhibitor increased GLI2 expression despite 
GLI1 expression being reduced. This is interesting as GLI1 and GLI2 are part of 
a feedback loop therefore if GLI1 is suppressed then GLI2 should also be 
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suppressed (Regl et al., 2002). The induction of GLI2 may occur to compensate 
for the suppression of GLI1. Also, the data suggest that GLI1 and GLI2 can be 
expressed independently of each other i.e. GLI2 expression does not depend 
on GLI1 expression. To use such inhibitors for therapy may therefore induce 
GLI2 which in turn could facilitate BCC  growth. A study where the targeting of 
both the EGFR and HH pathways reduced mouse BCC growth (Schnidar et al., 
2009) could therefore be interpreted as the EGFR inhibitor reducing GLI1 and 
the HH inhibitor repressing GLI2. If the MEK/ERK cascade is disrupted by the 
EGFR inhibitor, it is likely that both GLI1 and GLI2 are reduced.
Despite demonstrating that the ERK pathway is more active in NEB1 and N/Tert 
cells due to the suppression of PTCH1, this does not correlate in BCC tissue. 
Immunohistological studies of pERK and pAKT in BCC tissue show that neither 
protein is active in BCC (Neill et al., 2008; Hafner et al., 2012). We have done 
extensive analysis of EGFR signalling in BCCs and confirmed that pERK is not 
expressed in non-aggressive human BCCs. Interestingly, we have also shown 
that human BCCs express pMEK so why it does not phosphorylate its principal 
target ERK (the un-phosphorylated protein is expressed in the tumours) is 
surprising and under further investigation. Moreover, pERK is not expressed in 
mouse BCCs whereas pMEK is abundant (unpublished data).
The expression of pEGFR, pERK and pMEK was examined in 15 non-invasive 
and 14 invasive human BCCs. All phospho-proteins were expressed in normal 
and tumour associated epidermis (nuclear/cytoplasmic) but whereas pEGFR 
and pMEK were also present in all tumours (albeit at varying levels and with no 
apparent correlation), pERK was consistently absent in non-invasive BCCs; 
pERK staining was slightly higher in invasive tumour islands but the main 
feature of these samples was that pERK was often localized to the stroma. 
pERK (but not pMEK) was dramatically absent compared to the epidermis. 
Conversely, pERK (but not pMEK) was expressed in the stromal cells of a more 
aggressive BCC-like variant which correlates with the presence of stromal 
pERK in invasive human BCC.
As pEGFR was localized in the nucleus in nodular BCCs and in NEB1-
shPTCH1 cells, it is possible that this could account for the global reduction of 
pERK due to reduced EGFR activity  at the cell membrane. Analysis of the 
EGFR signalling in human tumors reveals that the canonical pathway is not fully 
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active in BCC and that further work is required to determine if and how 
components of the pathway warrant therapeutic attention. 
Indeed, whether or not loss of ERK activity is important for tumour formation 
these data reveal that the nature of EGFR sinalling( including how it interacts 
with HH signalling) in BCC biology is complex and that further reserach is 
required to determine the suitability of components of this pathway  thearapeutic 
intervention.
Moreover, we are currently setting up the Ptch+/- colony to continue these 
experiments and to bear out that NMYC oncogene is a Shh downstream 
effector and high expression of N-Myc protein is a frequent event in BCC 
predominantly in more aggressive subtypes. If these findings were confirmed 
novel systemic antigene inhibition strategies could be a promising option for 
therapy-refractory BCC.
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